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ABSTRACT 
Parkinson Disease is a progressive neurodegenerative disorder resulting from the 
premature destruction or improper function of dopamine producing neurons in the 
striatum of the brain. Symptoms include resting tremor, bradykinesia, rigidity, postural 
instability, gait abnormality and additional severe cognitive impairment.  Although 
Parkinson Disease has historically been thought of as a disease with sporadic origin, there 
are a number of genetic links and specific gene mutations found conserved across 
patients.  These mutations are typically found in genes responsible for the proper 
functioning of proteasome activity or intracellular organelle homeostasis.  The upkeep 
and repair of mitochondria involves a number of components including Pink1, Parkin, 
and the Peroxisome-proliferator-activated receptor coactivator (PGC) family of genes.  
The PGC family of genes have a single homologue in Drosophila melanogaster known as 
spargel.  In Chapter Two, I characterized this gene in neuronal tissues and found that 
altered gene activity in dopaminergic neurons leads to a decrease in longevity and 
locomotor ability over time, indicative of a Parkinson Disease like phenotype.  In Homo 
sapiens the PGC family genes are regulated through the activity of an intermediate 
protein, PARIS.  In Chapter Five I identified three potential homologues of the PARIS 
gene in D. melanogaster and compared altered expression of them in neuronal tissues 
resulting in the identification of a strong PARIS candidate and two novel genes involved 
in neuronal development.  The proteasome complex acts upon and destroys proteins 
targeted for destruction by addition of a ubiquitin moiety.  This process is undertaken by 
ubiquitin ligase complexes.  The target specific component of many of these complexes 
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are the F-box genes.  Chapters Three and Four characterize two F-box genes implicated in 
H. sapiens PD and identifies putative D. melanogaster gene homologs.   The results of 
this thesis provide expanded knowledge of both confirmed and putative D. melanogaster 
homologues of H. sapiens disease related genes and new model systems with which 
future study of disease mechanisms may be carried out. 
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Chapter 1 – Introduction and Overview 
1.1. Mediating Cell Survival and Cell Death 
 Whole organism survival and longevity depends largely on the ability of 
individual cells to adapt and respond to stressful conditions.  When stress is placed upon a 
cell, either from external trauma or the impaired function of internal components, pro-
survival pathways are activated.  Pro-survival pathways seek to restore normal cell 
functionality by identifying and relieving cellular stressors and include anti-oxidant 
compounds, heat shock proteins, proteasomal machinery and elements such as the 
unfolded protein response of the endoplasmic reticulum (Jager et al., 2012; Samali & 
Cotter, 1996; Trachootham et al., 2008).  If a stress is severe enough and repair is not 
possible, cell death pathways will be activated.  Cell death can occur in a variety of ways 
through programmed modes of cell death, such as apoptosis and autophagic cell death to 
necrosis (Ashkenazi & Salvesen, 2014).  This can affect not just the cell in question but 
also surrounding cells, and the final decision to undergo cell death can come from internal 
or external sources.   
 When the pro-survival mechanisms of a cell are unable to alleviate a stressful 
condition and cell death signals are activated there is a negative consequence on the 
whole organism as a result of premature cell death such as in the case of mitochondrial 
mediate apoptotic cascades (Estaquier et al., 2012).  Despite this, it is more favourable for 
a single cell to be sacrificed than for neighbouring cells to be subjected to the initial cause 
of stress in a process known as cell altruism (Allsopp & Fazakerley, 2000).  The 
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continued existence of dysfunctional cells can have more severe consequences.  Mutation 
to a number of genes involved in these stress response pathways have been linked to 
disease pathogenesis.  Failure to properly mediate the pathways of cell survival and cell 
death can lead to a number of undesired consequences including whole organism 
mortality.  Understanding and characterizing the genes responsible for the upkeep and 
proper function of these mechanisms may lead to preventative treatment and new 
therapeutic options for existing conditions related to the dysfunction of survival and death 
pathways.   
1.1.1. Premature Cell Death and Degenerative Disease 
 Degenerative diseases are progressive chronic conditions that may cause a 
deterioration of a tissue or group of cells over time.  This accumulated premature loss of 
cells can be broken down into two specific branches: neurodegenerative and muscular 
degenerative.  Common neurodegenerative diseases include Parkinson Disease (PD), 
Alzheimer Disease (AD), Huntington Disease (HD),  and Multiple Sclerosis (MS), while 
the most common muscular degenerative diseases are Sporadic Inclusion-Body Myositis 
(s-IBM) Spinal Muscle Atrophy (SMA) and Amyotrophic Lateral Sclerosis (ALS) 
(Merzetti & Staveley, 2013; Sendtner, 2014).  The progressive nature of these diseases 
has resulted in the development of therapeutic agents.  Unfortunately, most of these 
agents aim to reduce symptom severity and do not address the underlying cause of 
disease.   
 Originally, the cause of degenerative disease was linked primarily to 
environmental factors (Chin-Chan et al., 2015).  New advances in whole genome 
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sequencing technologies and genetic approaches have shown that many common genetic 
risk loci are found in patients with these diseases and that many of them are directly 
inheritable.  To better understand the initial cause of disease, it is essential to determine 
what genes or metabolic pathways are commonly affected in inherited variants.  Improper 
function of cellular pathways including mitochondrial maintenance and upkeep, 
autophagy and proteasome function caused by specific gene mutations have been 
implicated in disease, (Bajic et al., 2012; Lionaki et al., 2015; Menzies et al., 2015).  
Determining the genes and pathways related to these processes that contribute to 
degenerative disease may lead to new options for treatment and prevention. 
1.1.2. Parkinson Disease 
 PD is a common and progressive neurodegenerative condition that is estimated to 
afflict 1% of all individuals over the age of 60 worldwide (Lew, 2007).  The initial cause 
of sporadic PD dysfunction is unknown.  Clinical symptoms include resting tremor, 
bradykinesia, rigidity and postural instability.  In addition to these classical symptoms, 
recent discoveries have shown that additional effects may include loss of memory and 
depression as the number of areas in the brain affected by degeneration increase 
(Williams-Gray et al., 2006; Wirdefeldt et al., 2011).  These symptoms are caused by a 
decrease in the amount of the neurotransmitter dopamine available in the striatum area of 
the brain and characterized by an accumulation of harmful protein aggregates known as 
Lewy bodies in the neurons of the substantia nigra pars compacta and destruction of 
neurons in this region  (Olanow & McNaught, 2011).  It is believed that the eventual 
dysfunction and breakdown of these neurons is responsible for the symptoms and 
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pathology of PD (Bekris et al., 2010).  The pathways leading to this neuronal breakdown 
are not yet fully elucidated and, as such, the exact cause of PD is not currently 
understood. 
 Pathogenesis of PD occurs by disrupting the neurotransmitter mediated signal 
cascade from the prefrontal cortex to the motor and emotional control areas found in the 
midbrain.  Destruction of neuronal tissues in the substantia nigra pars compacta leads to 
a decreased amount of dopamine being present across the striatum (Obeso et al., 2008).  
Decreased dopamine availability leads to diminished cellular response and eventual loss 
of motor control.  As disease progression continues, additional areas of the brain involved 
in processes such as emotional control and memory are also affected by this gradual loss 
of neurons, resulting in the non-motor symptoms common in late stage PD (Narayanan et 
al., 2013).  Although dopamine replacement therapy is the most common approach to 
treating PD, this therapy does not stop disease progression and the early mortality 
associated with PD remains. 
 It was initially believed that PD was caused by a number of environmental factors, 
including chemical exposure, brain trauma, obesity, diabetes and age (Vanitallie, 2008).  
Although these stressors may lead to sporadic forms of PD, there is also a great deal of 
evidence to show that many forms of PD are caused by genetic factors (Bereznai & 
Molnar, 2009).  Since the sequencing of the human genome, efforts have been made to 
determine what genetic risk factors may make a patient more susceptible to disease onset 
in response to environmental factors.  A comparison of whole genomes of PD patients has 
revealed a number of genetic risk variants not found in control groups (Labbe & Ross, 
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2014). The current belief is that PD may be caused solely by inherited or environmental 
means, but the majority of cases likely stem from a combination of genetic risk factors 
and environmental exposure. 
 At a molecular level, the loss of dopaminergic neurons (DA) may be directly or 
indirectly caused by a number of factors, including, but not limited to cellular stress and 
oxidation, impaired cellular dynamics, signal cascade dysfunction, or improper 
functioning organelles (Choi et al., 2011; Levy et al., 2009; Pedrosa & Soares-da-Silva, 
2002).  Genes responsible for a number of diverse yet important cellular functions, such 
as ubiquitination, cellular dynamics, proteasomal activity and biogenesis of new 
organelles, have been implicated in PD; Table 1 shows a list of these genes and their 
“Park” family designation (a nomenclature used to denote their putative link to PD).  
Although these genes are diverse in nature, they share a number of similar functions 
including ubiquitin ligase activity, serine protease activity, protein transport, 
neuroprotective effects, tyrosine kinase signaling and initiation of translation (Anderson 
et al., 2007; Kinghorn et al., 2015; Labbe & Ross, 2014; Orenstein et al., 2013; Park et 
al., 2014; Ragland et al., 2009; Ross et al., 2015; Ruiz-Martinez et al., 2015; Vande 
Walle et al., 2008; Xiu et al., 2013; Zondler et al., 2014).  Identifying the functions of 
orthologous genes in a model organism may lead to new therapeutic targets and better 
understanding of PD. 
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Table 1: Common Parkinson Disease genes and functions in Homo sapiens. 
Name 
 
Inheritance 
 
Gene Function 
 
PARK1 
 
Autosomal Dominant 
 
SNCA 
 
Synaptic vesicle supply, forms Lewy Bodies 
when mutated PARK2 Autosomal Recessive 
 
Parkin 
 
E3 ubiq itin ligase 
PARK3 Risk-Factor 
 
FBXO48 
 
E3 ubiquitin ligase 
PARK4 Autosomal Dominant 
 
SNCA 
 
Synonym for PARK1 
PARK5 Autosomal Dominant 
 
UCHL1 
 
C-terminal hydrolase deubiquitinating enzyme 
PARK6 Autosomal Recessive 
 
PINK1 
 
Serine / threonine-protein kinase, recruits 
Parkin PARK7 Autosomal Recessive 
 
DJ-1 
 
Neuroprotective role, prevents α-synuclein 
aggregation PARK8 Autosomal Dominant 
 
LRRK2 
 
Macro ut phagy, chaperone-mediated 
autophagy PARK9 Autosomal Recessive 
 
ATP13A2 
 
Zinc omeostasis 
PARK1
0 
Risk-Factor 
 
RNF11 
 
E3 ubiquitin ligase (unconfirmed candidate) 
 PARK1
1 
Autosomal Dominant 
 
GIGYF2 
 
Tyrosine kinase receptor signaling 
 PARK1
2 
Risk-Factor 
 
unknown 
 
Unknown 
 PARK1
3 
Autosomal Dominant 
 
HTRA2 
 
Mitochondrial serine protease 
 PARK1
4 
Autosomal Recessive 
 
PLA2G6 
 
Mitochondrial lipid balance 
 PARK1
5 
Autosomal Recessive 
 
FBXO7 
 
E3 ubiquitin ligase 
 PARK1
6 
Risk-Factor 
 
unknown 
 
Unknown 
 PARK1
7 
Autosomal Dominant 
 
VPS35 
 
Protein transport 
 PARK1
8 
Autosomal Dominant 
 
EIF4G1 
 
Translation initiation factor 
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1.1.3. The Role of Mitochondria in Parkinson Disease 
 Mitochondria are important and necessary components of nearly all eukaryotic 
cells.  They are often referred to as the “power plant” of the cell due to their function in 
the creation of adenosine triphosphate (ATP) for use as chemical energy.  Mitochondria 
also have additional important functions in cellular growth and death signal control, 
cellular signaling, and differentiation (Campbell, 2006).  With mitochondrial involvement 
in such diverse and important cellular functions, it is not surprising that the breakdown or 
dysfunction of mitochondria may result in a number of disorders, including, but not 
limited to neuro-, and musculo degenerative diseases (Wallace & Fan, 2009).  Many of 
these disorders are caused by defective removal of damaged or non-functional 
mitochondria and a subsequent lack in de novo synthesis of replacement organelles 
(Huang & Manton, 2004).  Thus, characterizing and understanding the function of the 
genes that regulate and monitor the health of these mitochondria is an essential step in 
determining potential disease prevention strategies. 
 Mitochondria have a number of characteristics that make them key intermediaries 
in the pathogenesis of many forms of degenerative disease.  They are the site of chemical 
energy production through the activity of five protein complexes located within the inner 
mitochondrial membrane.  This process often results in electron leakage which, in turn, 
leads to the formation of toxic reactive oxygen species (ROS) (Rigoulet et al., 2011).  
These ROS are produced in the mitochondrial matrix.  Mitochondrial DNA (mtDNA) is 
also found in the matrix and the close proximity of these ROS and easily damaged 
mtDNA can lead to organelle dysfunction and breakdown.  In order to combat this 
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potential destruction, mitochondria are equipped with intra-organellular pathways that 
lead to apoptosis when severe dysfunction or ROS buildup is detected (Sinha et al., 
2013).  Although these apoptotic pathways are in place to prevent the spread of harmful 
material to neighbouring cells, they also result in premature cell death which in many 
tissues ultimately causes degenerative disease phenotypes. 
 There are a number of gene variants that have been identified in Homo sapiens 
cases of PD that show importance in mitochondrial function.  One of the most studied 
pathways relating to mitochondrial upkeep and turnover is the Pink1/Parkin pathway 
(Figure 1) (Eiyama & Okamoto, 2015).  PARKIN (PARK2) is a component of a multi-
protein E3 ubiquitin ligase that leads to the ubiquitination and subsequent destruction of 
cellular components (Narendra et al., 2008).  Mutations to the Parkin gene result in the 
degeneration of DA neurons, proposed to be due to the aggregation of multiple 
dysfunctional mitochondria that eventually lead to apoptotic cell death (Greene et al., 
2003).  Phosphatase and tensin homologue induced putative kinase 1 (PINK1, PARK6) is 
a serine / threonine-protein kinase that acts by recruiting PARKIN to damaged 
mitochondria (Koh & Chung, 2011).  Like Parkin, mutations to PINK1 lead to 
degeneration and dysfunction of DA neurons (Yang et al., 2006).  A third player in this 
pathway, Mitofusin2 (Mfn2), acts as the mediator between the PARKIN and PINK1 
proteins (Pallanck, 2013).  MFN2 is an outer membrane protein that functions in the 
process of mitochondrial fusion (Santel & Fuller, 2001).  PARKIN recruitment is 
dependent upon the phosphorylation of MFN2 by PINK1 (Y. Chen & Dorn, 2013).  
These proteins act together in concert to remove any damaged or dysfunctional  
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Figure 1: The Parkin / Pink1 / Mfn2 pathway of mitophagy.  Under conditions of stress mitochondria 
undergo a change in polarization causing an accumulation of PINK1 at the outer membrane.  PINK1 
phosphorylates MFN2 which in turn attracts PARKIN.  PARKIN, through activity as an E3 ubiquitin ligase, 
marks the damaged mitochondria for destruction.  This process results in mitophagy. 
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mitochondria that may be present in a process known as mitophagy.  Mutation in either of 
these genes negates the cell’s ability to target and remove dysfunctional mitochondria 
which in turn leads to cell death. 
1.1.4. The Ubiquitin Proteasome System in Parkinson Disease 
 The ability to respond and adapt to traumatic events within a cell is an essential 
and necessary part of homeostasis.  Damaged cellular components must be either repaired 
or removed to prevent the premature destruction of the cell as a whole.  There are specific 
components of the cell responsible for marking abnormal or impaired proteins for 
destruction.  One such marker is addition of the protein ubiquitin.  Ubiquitin is a 76 
amino acid peptide which contains 7 lysine residues, allowing for the addition of single or 
multiple ubiquitin residues to a protein of interest (Wilkinson, 2005).  The addition of 
ubiquitin moieties is mediated by a complex known as the Ubiquitin Proteasome System 
(UPS), while the process of protein destruction is undertaken by the 26S proteasome 
(Atkin & Paulson, 2014).  Impairment or failure of either the UPS or 26S proteasome 
leads to a buildup of dysfunctional proteins within the cell and may eventually cause 
death.   
 The UPS works through the action of three enzymes named E1, E2 and E3.  E1, 
known as the activating enzyme, creates a thioester bond between a cysteine moiety of 
the E1 enzyme and the ubiquitin protein via ATP hydrolysis.  This ubiquitin protein is 
then transferred to E2, known as the conjugating enzyme, once again at an active site 
cysteine.  The final step sees the E3 ligating enzyme catalyze attachment of the ubiquitin 
to a lysine of the target protein (Wilkinson, 2005).    In this system, the E3 ligating 
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enzymes are in highest abundance as they are responsible for targeting the protein of 
interest.  They may be broken down into two main classes: Homologous to the E6-AP 
Carboxyl Terminus (HECT) and Really Interesting New Gene (RING) domain E3s 
(Metzger et al., 2012).  The main difference between HECT and RING E3 ubiquitin 
ligases lies in the mode of ubiquitin transfer.  While HECT domain E3s will directly bind 
the ubiquitin moiety via thioester linkage, the RING family E3s catalyze the addition of 
ubiquitin by directing the E2 enzyme toward the protein to be targeted via a zinc binding 
motif (Huibregtse et al., 1995; Lorick et al., 1999).  Mutation to any of the components in 
this process leads to a buildup of protein aggregates due to a reduced efficiency of 
proteolysis. 
 The accumulation of harmful protein aggregates is a common hallmark of 
neurodegenerative disease and a number of inherited forms of PD have been linked to 
defects in UPS function.  Additionally, it has been found that impaired UPS activity 
causes a loss of synaptic connections in a dose dependent manner, causing symptoms 
prior to actual tissue loss (Bajic et al., 2012; Ehlers, 2003).  Of the 18 PARK genes, 5 
have functions related to the UPS, with 4 of those being E3 ubiquitin ligases (Table 1).  
Pink1 and Parkin are two of these genes and have been discussed in detail above, while 
the other two are FBXO7 and FBXO48.  F-box proteins function as part of the multi-
protein Skp1-Cullin1-F-box (SCF) ubiquitin ligase complex (Cardozo & Pagano, 2004).  
This specific sub-family of UPS ligases will be discussed at length in section 1.3.  The 
fifth PARK gene related to UPS function is Synuclein alpha (SNCA).   
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Mutation to the SNCA gene (Park 1/4), which codes for the α-SYNUCLEIN protein, leads 
to autosomal dominant forms of PD and aggregate protein clusters (Deng & Yuan, 2014).  
These intracellular proteinaceous inclusions have been named Lewy Bodies (LBs) 
(Takeda et al., 2008).  LBs are protein aggregates consisting mainly of α-SYNUCLEIN 
protein polymers bound to ubiquitin molecules (Baba et al., 1998).  α-SYNUCLEIN is a 
small soluble protein capable of binding to many intracellular components, including the 
microtubule stabilizing molecule TAU, due to its small amphipathic structure (Payton et 
al., 2001).  In addition to being present in the neurons of many PD affected individuals, 
mutation of the α-synuclein gene has been shown to directly lead to dominant early onset 
PD (Polymeropoulos et al., 1997).  The role of aggregate α-SYNUCLEIN and how 
accumulation of these LBs leads to improper cell function and eventual neuronal death is 
currently under investigation.   
 LBs may contribute to the overall instability of internal cellular components 
leading to increased cellular oxidative stress, decreased organelle movement and 
disrupted protein function (Jenner & Olanow, 1998).  Neuronal cells are especially 
vulnerable to reduction in energy due to their high energetic requirements and disruption 
of mitochondrial dynamics due to these protein clusters may be a significant sign of 
impending cell destruction (Detmer & Chan, 2007).  It is of particular interest that recent 
evidence has been found supporting the theory that these LBs may be able to move 
between neurons, perhaps presenting a prion-like mode of pathology in disease 
progression (George et al., 2013).  Although cells are equipped to deal with abnormal 
protein aggregates by means of proteosomal machinery, these LBs seem to remain intact 
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in models of disease, suggesting that improper function of intracellular proteasomal 
components may be one of the first steps in disease progression. 
1.1.5. Drosophila melanogaster as a Model of Parkinson Disease 
 The study of human degenerative disease is complicated by many factors, 
including long term disease development, gene redundancy and ethical constraints.  As a 
result, many of the current treatments for degenerative disorders focus on alleviation of 
symptoms and do not address the underlying cause of disease.  Studying these complex 
diseases in an organism such as D. melanogaster alleviate many of these constraints and 
offer a model of disease to identify and characterize genetic pathways conserved between 
organisms.  Functional homologues of approximately 75% of human disease genes have 
been characterized in D. melanogaster and it is possible that uncharacterized disease 
homologues may still be discovered (Pandey & Nichols, 2011).  D. melanogaster are 
small and easy to culture with a generation time of 10 days at 25°C, which allows quick 
generation of desired genotypes as well as a relatively small window to investigate 
differences in lifespan.  Insertion of foreign genes into the genome of Drosophila via the 
Gal4-UAS transgene system is particularly useful (Brand & Perrimon, 1993) (Figure 2).    
The Gal4-UAS system uses the yeast transcription factor target, Upstream Activating 
Sequence (UAS), to drive expression of a gene of interest under control of the yeast 
transcription factor Gal4, which is under the control of a tissue specific enhancer.  The 
Gal4-UAS system can be used to ectopically express genes of interest or to determine the 
effect of a transcript knockdown via RNAi expression.  This is a powerful tool that allows 
characterization of altered gene function, not just in a whole organism but in individual 
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tissues associated with disease by the expression of targeted, double stranded RNA that is 
converted into an active form by the enzyme DICER and introduced to the RNA induced 
silencing complex where it is converted into an active inhibitor form(Clemens et al., 
2000).   
 Although the nervous system of D. melanogaster is, as a whole, less complex then 
that of H. sapiens, a number of important pathways in cancer, immunity and development 
are conserved (Pires-daSilva & Sommer, 2003).  Furthermore, the ectopic expression of 
mutant gene products that cause inherited H. sapiens diseases such as polyglutamine 
repeats have been modelled in D. melanogaster (Krench & Littleton, 2013).  Thus, D. 
melanogaster has been used as an efficient and inexpensive model of other 
neurodegenerative diseases including PD (Baba et al., 1998).  DA neuron production of 
dopamine causes similar downstream effects in both D. melanogaster and H. sapiens 
including wakefulness, sleep, arousal, learning behaviors and motor coordination 
(Yamamoto & Seto, 2014).  A decrease in locomotor ability and longevity has been 
associated with a decrease in activity of dopamine precursors in D. melanogaster, 
providing a link between observed H. sapiens phenotypes and fly consequences of DA 
expression loss (Wills et al., 2010).  Taken together, these previous findings make the DA 
neurons of D. melanogaster an ideal system to assay H. sapiens neurodegenerative 
disease and expected phenotypes of disease causing genes would be a decrease in 
longevity, impaired locomotor ability and neuronal destruction. 
 In addition to DA neurons which may be assayed for degenerative phenotypes 
based on similarities between species, the neuron-rich Drosophila eye is a highly 
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sensitive system to determine the effects of gene alteration on neuronal cells (Tsachaki & 
Sprecher, 2012).  Two well defined tissues formed from neuronal precursors compose the 
outer layer of the eye: ommatidia and bristles (Cook et al., 2011).  Standard D. 
melanogaster compound eyes consist of between 750-800 ommatidia and 575-625 inter-
ommatidia bristles (Ready et al., 1976).  Ommatidia contain pre-determined array of 
photoreceptor cells that have been shown to be susceptible to neurodegenerative effects 
(Colley, 2012).  Thus, it is possible to assess the effect of mutations in genes related to H. 
sapiens neurodegenerative disease in D. melanogaster by eye specific expression.  This 
technique offers two distinct advantages: the first is that the phenotypes of destruction 
associated with neurodegeneration in the eye are readily observable with a scanning 
electron microscope, the second is that the fly develops normally in all other aspects as 
the eye is a dispensable organ for survival (Sang & Jackson, 2005).  Finally, multiple 
Drosophila genomes have been sequenced, this allows the use of bioinformatics analyses 
to determine regions of fly proteins that correspond to known human proteins (A. G. 
Clark et al., 2007).  Taken together, these advantages make D. melanogaster an excellent 
organism to study complex human degenerative disease such as PD. 
 Although D. melanogaster provides a number of advantages as a model organism 
for modeling neurodegenerative disease it also comes with a number of disadvantages to 
performing assays in human cell culture or PD patients.  One important consideration is 
that there is no readily quantifiable measure of complex behavior in flies and so the 
neurodegenerative phenotypes associated with gene dysfunction can only infer that there 
is an effect, not how that effect comes about (Prussing et al., 2013).  Models of H. sapiens 
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disease in lower organisms also often results in therapeutic effects not conserved across 
species, however, this effect is also found in H. sapiens cell culture. 
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Figure 2: The Gal4-UAS transgene system of Drosophila.  The insertion of two Saccharomyces 
cerevisiae genes into Drosophila allows specific gene expression.  The transcription factor, Gal4, causes an 
increase in transcription of any gene inserted downstream of the target sequence UAS.  Insertion of the 
Gal4 gene downstream of a promoter of interest and the UAS upstream of a gene of interest allows the 
promoter specific expression of that gene. 
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1.2. The PGC Family of Proteins 
 The peroxisome proliferation activated co-receptor gamma (PCG) family of genes 
have been characterized as regulatory transcription factors in pathways of mitochondrial 
biogenesis (Krempler et al., 2000).  Functionally, they interact with the nuclear 
peroxisome proliferator-activated receptor gamma (PPAR-γ) and act as docking platforms 
for additional proteins to remodel chromatin and initiate the assembly of basal 
transcription machinery leading to increased gene expression (Baar, 2004).  Mutant PGC 
proteins have been implicated as causative factors in a number of diseases including AD, 
HD, PD, and stroke (Chen et al., 2012; Johri et al., 2013).  The PGC family contains three 
genes with partial functional redundancy: PGC-1α, PGC-1β and PRC (also known as 
PGC-1γ).  While both PGC-1α and PGC-1β are expressed predominantly in tissues with 
high energy requirements, PRC is expressed equally across various tissues (Andersson & 
Scarpulla, 2001).  Although PGC-1α and PGC-1β show similar expression patterns, 
PGC-1α is upregulated under conditions of stress, such as endurance exercise, while 
PGC-1β is not (Meirhaeghe et al., 2003; Mortensen et al., 2007).  This suggests that 
PGC-1β has a role in the basal level of gene expression in tissues with high energetic 
requirements, while PGC-1α expression is likely more dependent upon stress related 
activation.   
1.2.1. PGC-1α, the Stress Responsive PGC Family Member 
 Of the three PGC proteins, PGC-1α is the most likely to be altered in models of 
disease based on its upregulation in conditions of stress.  This effect has been documented 
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in a number of tissues; it is upregulated in response to adrenergic stimulation in cold 
exposure to initiate a shivering response, induced in muscle fibers during endurance 
exercise, and dramatically up-regulated in conditions of fasting (Baar et al., 2002; 
Puigserver et al., 1998; Yoon et al., 2001).  PGC-1α has also been found to be involved 
in pathways of mitochondrial biogenesis in various tissues including the liver and brain 
(Uldry et al., 2006).  Medical data have shown that certain PGC-1α polymorphisms in 
human populations are linked to a higher risk or earlier age of onset of PD symptoms 
(Clark et al., 2011).  The PGC-1α mediated mitochondrial biogenesis pathway involves 
the activity of 5 genes.  PGC-1α initiates activity of a downstream transcription factor, 
Nuclear Respiratory Factor-1 (NRF-1) (DeSimone et al., 1996).  A second mitochondrial 
transcription factor, Nuclear Respiratory Factor-2 (NRF-2), has been found to operate in 
a parallel pathway to PGC-1α, also leading to mitochondrial growth and biogenesis 
(Tiefenbock et al., 2009).   
 Transcriptional regulation of PGC-1α is controlled by a negative regulator, Parkin 
Interacting Substrate (PARIS).  When PARIS is present, it binds to the upstream region of 
the PGC-1α gene and prevents transcriptional activity from occurring.  This prevents 
PGC-1α transcription and reduces the amount of mitochondrial biogenesis of the cell 
(Castillo-Quan, 2011).  The PARIS protein consists of two distinct motifs, an N-terminal 
Kruppel Associated Box (KRAB) domain and a C-terminal C2HC/C2H2 zinc-finger 
binding domain (Shin et al., 2011).  Proteins containing KRAB domains have commonly 
been found to act as transcriptional repressors via interaction with Kruppel Association 
Protein-1 (KAP-1) (Witzgall et al., 1994).  Work by Shin et al. (2011) found the 
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consensus DNA binding sequence target of PARIS to be the insulin response element 
TATTTT(T/G), which is most often found upstream of genes involved in energy 
metabolism including PGC-1α (Mounier & Posner, 2006).  The PARIS protein was 
originally isolated by a yeast two-hybrid screen using PARKIN as bait.  Further analysis 
of the interaction between these two proteins found that PARKIN is responsible for the 
ubiquitin dependent control of PARIS levels in the cell (Shin et al., 2011).  This newly 
discovered role in mitochondrial biogenesis in tandem with its activity as a mediator of 
mitochondrial upkeep and turnover shows Parkin as a master regulator of overall 
mitochondrial concentration in the cell and a necessary component of the PGC-1α 
pathway. 
1.2.2. The Drosophila melanogaster PGC Family Homologue, spargel 
 The three members of the PGC family in mammals are transcription factors that 
stimulate the same response elements.  Furthermore, PRC is expressed at a basal level in 
almost all tissues while PGC-1β and PGC-1α are expressed at a basal level in all tissues 
with high energy requirements (Andersson & Scarpulla, 2001; Kamei et al., 2003).  This 
overlapping pattern of expression makes the study of altered PGC family function 
difficult.  Although studies in mice have focused on identifying the differences between 
these genes by using a double-knockout gene approach, elimination of all three genes is 
lethal (Lai et al., 2008).  There is only a single PGC family homologue found in 
Drosophila melanogaster, spargel (srl).  spargel mutant flies have a “lean” phenotype 
that is typical of mutations that affect growth and proliferation, and have been shown to 
affect mitochondrial fitness in vivo (Tiefenbock et al., 2009).  Similar to PGC-1α, srl 
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activity has been linked to pathways of mitochondrial biogenesis and insulin signaling, 
exercise endurance and has been shown to interact with the D. melanogaster homologues 
of Parkin and Pink1 (Mukherjee & Duttaroy, 2013; Tiefenbock et al., 2010; Tinkerhess et 
al., 2012).  Characterizing the consequence of altered gene function of srl in the neurons 
of D. melanogaster will provide additional insight into the mechanisms and common 
pathways shared with the Homo sapiens PGC-1α homologue. 
1.3. SCF Ubiquitin Ligase Complexes and F-box Proteins 
 Skp1-Cullin1-F-box (SCF) ubiquitin ligase complexes are the most common class 
of RING E3 ubiquitin ligases and are formed by the binding of CULLIN1 to ROC1, 
SKP1 and an F-box protein (Lyapina et al., 1998).  The activity of this multi-protein 
complex can be increased or decreased by the binding of co-factors to the C-terminal of 
the CULLIN1 protein, which provides an important role in regulating function (Duda et 
al., 2008).  Of all the components of this complex, perhaps the most important are the F-
box proteins, which convey substrate specificity for ubiquitination and through the 
activity of stabilizing co-factors respond to changes in cellular landscape and various 
stimuli (Lee & Diehl, 2014).  Mutation to components of SCF ubiquitin ligase complexes 
has been implicated in a number of disease models due to the breakdown and decrease in 
cellular proteasomal activity associated with a lack of ubiquitination (Skaar et al., 2013).  
Understanding how specific proteins function within this complex, specifically the 
targeting F-box proteins, is an important step in determining how to combat disease 
causing mutations.   
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 F-box proteins are named after Cyclin F, the first F-box gene to be discovered, 
and are characterized by a specific and highly conserved C-terminal F-box domain 
approximately 50 amino acids in length (Bai et al., 1994).  Classification of F-box 
proteins is based upon the substrate interacting domain present in each protein.  There are 
three classes of these domains: the WD40 repeat domain, the leucine rich repeat domain 
(LRR) and a third class consisting of all domains that do not fit into the first two termed 
the F-box other or “O” domain.  F-box WD40 repeat domains contain a short motif of 
approximately 40 amino acids ending with a tryptophan and aspartic acid residue, and are 
referred to as FBXW proteins  (Neer et al., 1994).  LRR domains are characterized by a 
repeat of leucine residues, which functions as an important staging ground for protein-
protein interactions, and are designated FBXL proteins (Kobe & Deisenhofer, 1994).  
FBXO proteins contain variable interacting regions, including carbohydrate binding 
proteins and sugar hydrolase (CASH), post synaptic density Drosophila disc large tumor 
suppressor and Zonula occludens-1 protein (PDZ), proline-rich and zinc finger domains 
(Cardozo & Pagano, 2004).  Although they differ widely in the composition of interacting 
domains, all F-box proteins serve the same targeting function in SCF ubiquitin ligase 
complexes.   
1.3.1. The FBXO7, FBXO9 and FBXO32 Sub-family of F-box Proteins 
 A number of F-box genes have been implicated in human disease.  Almost all 
have links to growth pathways that when mutated can cause abnormal growth and 
cancerous phenotypes but one specific sub-set of the FBXO family has been implicated 
specifically in degenerative conditions (Merzetti et al., 2013).  This sub-family contains 
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three genes: FBXO7, FBXO9 and FBXO32, however, to date only two of them have been 
directly linked to degenerative phenotypes (Cenciarelli et al., 1999).  Mutation to the 
FBXO7 (also known as PARK15) gene has been linked to a severe early onset form of PD 
known as Parkinson Pyramidal Syndrome (PPS) (Di Fonzo et al., 2009).  Mutation to the 
FBXO32 (also known as Atrogin-1) gene causes impaired function of cardiac myosin-
binding protein C (cMyBP-C), leading to autosomal dominant forms of hypertrophic 
cardiomyopathy (Mearini et al., 2010). Although not much information is currently 
available on the FBXO9 gene and no ubiquitination targets have been uncovered, it has 
been implicated in growth factor signaling in multiple myeloma (Fernandez-Saiz et al., 
2013).  It is clear that genes in this FBXO sub-family are active in pathways of disease 
and further study into the mechanisms by which they target and degrade proteins is 
required.   
 FBXO7 was initially identified as a ubiquitin ligase targeting the Hepatoma Up-
Regulated Protein (HURP) (Hsu et al., 2004).  FBXO7 has also been implicated in 
regulation of the cell cycle through interaction with cyclin proteins (Laman et al., 2005).  
As a ubiquitin ligase, the activity of the FBXO7 protein is not possible without the 
stabilizing activity of a co-factor, Proteasome Inhibitor 31 (PI31) (Kirk et al., 2008).  
Although PI31 is an essential component of the SCFBOX7 ubiquitin ligase construct, it 
also has an independent function as a binding inhibitor of the proteasome complex (Zaiss 
et al., 2002).  Thus, PI31 expression is a key regulator of proteasome activity: too little 
will prevent the proper targeting of the SCF complex while too much will prevent the 
response of proteasomal machinery to ubiquitinated targets (Li et al., 2014).  FBXO32 is 
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a muscle-specific ubiquitin ligase which is also known as Atrogin-1 (Bodine & Baehr, 
2014).  FBXO32 is upregulated in muscle wasting conditions in skeletal muscle and 
targets proteins essential in muscle synthesis, including Myogenic Differentiation 1 
(MyoD) and Eukaryotic translation initiation factor 3 subunit F (eIF3-F) (Lagirand-
Cantaloube et al., 2008; Tintignac et al., 2005).  FBXO7 and FBXO32 are essential 
ubiquitin ligases involved in a variety of pathways necessary for neuronal and muscular 
health.   
1.3.2. Potential FBXO7 and FBXO9 Homologues in Drosophila melanogaster 
 Many F-box genes have functional homologues found conserved between H. 
sapiens and D. melanogaster.  Of the 75 identified H. sapiens F-box proteins, 21 have a 
known D. melanogaster homologue (Dui et al., 2012; Jin et al., 2004) (Table 2).  These 
21 genes share function in various  physiological and biochemical pathways, including 
circadian rhythm, growth regulation, proteasomal degradation and muscle wasting 
(Merzetti et al., 2013).  Of these 21 genes, the three FBXO sub-family proteins, FBXO7, 
FBXO9 and FBXO32, all have putative homologues found in D. melanogaster.  The 
putative D. melanogaster homologue of FBXO7 is nutcracker (ntc), originally named for 
its role in the terminal differentiation of sperm cells and mutational phenotype of male 
sterility (Bader et al., 2010).  The putative D. melanogaster homologue and H. sapiens 
FBXO7 gene share a conserved function as ubiquitin ligase targeting components with a 
similar involvement in terminal differentiation of sperm cells.  Both ntc and FBXO7 have 
been implicated as potential factors in PD pathogenesis (Burchell et al., 2013).  D. 
melanogaster FBXO7 has also been associated with a homologue of PI31, showing that 
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stabilization of the SCF ubiquitin ligase complex is necessary between organisms (Bader 
et al., 2011).  In contrast FBXO9 has not been well characterized in D. melanogaster, but 
a putative homologue, CG5961, has been identified.  Studying the putative homologues 
of FBXO7 and FBXO9 in the simplified D. melanogaster system may lead to a better 
understanding of the pathways these genes control in disease models.   
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Table 2: F-box genes conserved between Drosophila melanogaster and Homo sapiens.  Many F-box 
genes share similar functions across species even if they are not necessarily homologous proteins (jetlag 
and overtime for example).  Table taken from (E. Merzetti et al., 2013).   
Gene Name  
(D. melanogaster) 
Identified Function 
(D. melanogaster) 
Gene Name  
(H. sapiens) 
Identified Function 
(H. sapiens) 
FBXW    
FBXW1 / slimb circadian rhythm  FBXW1 β-catenin degradation 
FBXW4 / ebi ARM pathway 
signaling 
FBXW4 β-catenin degradation 
FBXW5 TSC1/2 degradation FBXW5 TSC1/2    degradation 
FBXW7 / ago growth regulation FBXW7 growth regulation 
FBXL    
FBXL1 / Skp2 growth promoter FBXL1 / Skp2 mitotic spindle formation 
CG9003 unknown FBXL2 cyclin D2 degradation 
CG2010 unknown FBXL3 / 
overtime 
circadian rhythm 
CG1839 unknown FBXL4 lysine demethylase 
CG4221 unknown FBXL7 mitosis regulation 
FBXL14 / ppa centromere mediation FBXL14 SNAIL 1 degradation 
FBXL15 / jetlag circadian rhythm FBXL15 Smurf1 regulator 
CG32085 unknown FBXL16 tumor suppressor 
FBXL19 / kdm2 histone demethylase FBXL19 IL-33 degradation 
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FBXO    
FBXO1 / 
pallbearer 
phagocytosis FBXO28 phagosome maturation 
CG4911 unknown FBXO4 cyclin D1 regulation 
FBXO5 / rca mitosis regulation FBXO5 unknown 
CG6758 unknown FBXO6 Chk1 regulation 
FBXO7 / 
nutcracker 
sperm differentiation FBXO7 / 
PARK15 
sperm differentiation / PPS 
FBXO9 unknown FBXO9 growth signaling 
CG9461 unknown FBXO11 β-catenin degradation 
FBXO32 unknown FBXO32 / 
Atrogin-1 
muscle wasting 
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1.4. Research Goals 
 Previous research has found that genes which lead to PD like symptoms when 
mutated have similar biological functions in both Homo sapiens and Drosophila 
melanogaster.  The main goal of this research project was to identify models of PD in D. 
melanogaster that could be used as tools to expand knowledge of the pathways related to 
disease pathogenesis and onset.  The single D. melanogaster homologue of the well-
studied H. sapiens PGC gene family was determined to be a good target for disease 
modeling as it removes the complexity associated with analyzing three genes with 
overlapping expression patterns.  It has been documented that spargel mutants show 
severe growth defects and lean phenotypes in whole organisms, but the result of altered 
srl activity in specific tissues has been found to lead to variable effects.  To date, no study 
of the consequences of altered srl expression has been undertaken in dopaminergic 
neurons.  Thus, the initial goal of this research project was to assay srl mutant phenotypes 
in dopaminergic neurons and to determine if srl dysfunction leads to a PD phenotype.  
When it was determined that srl mutation had a profound effect on dopaminergic neurons 
and lead to a PD-like phenotype, a new goal to identify a potential D. melanogaster 
homologue of the transcriptional regulator PARIS was established.  Identification of a 
PARIS homologue in D. melanogaster would confirm the conservation of the 
mitochondrial overturn and biogenesis system between species. 
 In a parallel experiment, the consequence of altered expression of the highly 
conserved FBXO sub-family gene members FBXO7 and FBXO9 was determined.  The 
goal of this project was to once again characterize the putative homologues of genes 
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related to human disease phenotypes in D. melanogaster.  The putative FBXO7 
homologue nutcracker has been identified as a component of an SCF ubiquitin ligase 
complex in D. melanogaster.  Additionally, a D. melanogaster homologue of the 
stabilizing co-factor of FBXO7, PI31 has been identified in flies.  These proteins interact 
in a similar fashion in flies as they do in humans.  At the onset of this project no study 
had looked at the consequence of altered expression of ntc or PI31 in the dopaminergic 
neurons of flies.  The goal of this project was to determine if altered expression of either 
ntc or PI31 was sufficient to induce a PD like phenotype in D. melanogaster.  These 
genes were also assayed in an existing model of PD in which ectopic expression of α-
synuclein is driven in dopaminergic neurons.  To our knowledge this was the first time 
that these genes have been assayed together in a model of PD.   Finally, the putative D. 
melanogaster homologue of FBXO9 was assayed in neuronal tissue to determine if 
altered expression caused a disease-like phenotype.  As FBXO9 is not yet characterized in 
Homo sapiens or D. melanogaster but related sub-family members FBXO7 and FBXO32 
both show the capacity to cause disease, the goal of this project was to simply provide the 
first study into the function of this gene in flies.  The hypothesis of this work is that H. 
sapiens disease genes related to PD are conserved in D. melanogaster and the function of 
the protein these genes express is conserved among these organisms.  If this is true, I 
expect to be able to model neurodegenerative phenotypes in D. melanogaster which may 
then be used as a basic framework for future experiments to understanding the pathways 
associated with PD genes both in D. melanogaster and H. sapiens. 
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B.E. Staveley with input from E.M. Merzetti.  E.M. Merzetti performed the longevity, 
locomotor and eye analysis assays, carried out the bioinformatics and statistical analyses 
and drafted the initial manuscript.  B.E. Staveley participated in the supervision of the 
study and contributed to the final draft of the manuscript.  
 Chapter 3 is a version of a manuscript accepted for publication in the journal 
Genome (Merzetti, E.M., Dolomount, L.A., Staveley, B.E., The FBXO7 homologue 
nutcracker and binding partner PI31 in Drosophila melanogaster models of Parkinson 
Disease).  Contributions to this chapter were made by E.M. Merzetti, L.A. Dolomount 
and B.E. Staveley.  The project design was conceived and designed by L.A. Dolomount 
and B.E. Staveley with input after initial trials by E.M. Merzetti.  E.M. Merzetti 
performed the longevity, locomotor and eye analysis assays, carried out the 
bioinformatics and statistical analyses and drafted the initial manuscript.  B.E. Staveley 
participated in the supervision of the study and contributed to the final draft of the 
manuscript.   
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 Chapter 4 is a version of a manuscript published in Genetics and Molecular 
Research Merzetti, E.M., and B.E. Staveley, 2016. Altered expression of CG5961, a 
putative Drosophila melanogaster homologue of FBXO9, provides a new model of 
Parkinson disease. Genetics and Molecular Research 15 (2): gmr.15028579. DOI: 
http://dx.doi.org/10.4238/gmr.15028579).  Contributions to this chapter were made by 
E.M. Merzetti and B.E. Staveley.  The original experimental concept was drafted by B.E. 
Staveley with input from E.M. Merzetti.  E.M. Merzetti performed the longevity, 
locomotor and eye analysis assays, carried out the bioinformatics and statistical analyses 
and drafted the initial manuscript.  B.E. Staveley participated in the supervision of the 
study and contributed to the final draft of the manuscript. 
 Chapter 5 is a manuscript accepted for publication in the journal Genetics and 
Molecular Research (Merzetti, E.M., Staveley, B.E., Identification and evaluation of 
potential homologues of PARIS in Drosophila melanogaster).  Contributions to this 
chapter were made by E.M. Merzetti and B.E. Staveley.  The original experimental 
concept was drafted by B.E. Staveley with input from E.M. Merzetti.  E.M. Merzetti 
performed the longevity, locomotor and eye analysis assays, carried out the 
bioinformatics and statistical analyses and drafted the initial manuscript.  B.E. Staveley 
participated in the supervision of the study and contributed to the final draft of the 
manuscript. 
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Chapter 2 – spargel, the PGC-1α homologue, in models of Parkinson 
Disease in Drosophila melanogaster 
 
2.1. Introduction 
 Parkinson disease (PD) is a common and progressive neurological disease that is 
estimated to afflict 1% of all individuals over the age of 60 years worldwide (Lew, 2007).  
Although the direct cause of PD is as of yet unknown, the clinical symptoms include 
resting tremor, bradykinesia, rigidity and postural instability.  In addition to these 
classical symptoms recent discoveries have shown that effects may include cognitive 
impairment such as loss of memory and depression (Wirdefeldt et al., 2011).  These 
symptoms are caused by a decrease in the amount of dopamine available in the striatum 
area of the brain and in many cases characterized by an accumulation of harmful protein 
aggregates known as Lewy bodies in the neurons of the substantia nigra pars compacta 
(Olanow & McNaught, 2011).  The eventual dysfunction and breakdown of these neurons 
is responsible for the symptoms and pathology of PD (Bekris et al., 2010).  Both genetic 
and environmental factors have been found to contribute to PD, with many forms of the 
disease being attributed to a combination of the two.   Environmental factors include 
chemical exposure, brain trauma, obesity, diabetes and age (Vanitallie, 2008).  
Alternatively, there have been a number of familial cases of PD identified, which 
suggests a genetic link to certain forms of this disease (Bereznai & Molnar, 2009). This 
link is especially strong in the case of early onset PD which shows a bias towards genetic 
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causes, while environmental conditions seem to more often than not be linked to late 
onset PD (Wirdefeldt et al., 2011).  Identifying and analyzing the genes responsible for 
these inherited forms of PD may give rise to mechanisms of disease progression that are 
not presently understood.  Impaired neuronal activity has been shown to contribute to the 
lack of dopamine commonly associated with PD etiology.  Identifying the cause of this 
neuronal impairment may help lead to new, effective, strategies to combat PD. 
 As important and necessary components of eukaryotic cells, mitochondria are 
integral components in the creation of adenosine triphosphate (ATP) for use as chemical 
energy and are involved in other important pathways such as the control of cellular 
growth and death, cell signaling and differentiation (Campbell, 2006).  As the 
mitochondria are involved in such diverse and important cellular functions, it is not 
surprising that the breakdown or dysfunction of mitochondria may result in a number of 
disorders or diseases including, but not limited to, movement disorders such as PD 
(Greene et al., 2003).  Many of these disorders are caused by defective removal of 
damaged or non-functional mitochondria and a subsequent lack of de novo synthesis of 
new mitochondria to replace the aforementioned damaged organelles (Exner et al., 2012; 
Winklhofer & Haass, 2010).  Thus, the study of genes that regulate and monitor the health 
of mitochondria is a reasonable next step for determining potential disease prevention 
strategies. 
 The peroxisome proliferation activated co-receptor gamma (PCG) family of genes 
have been linked to mitochondrial biogenesis (Krempler et al., 2000).  PGC-1α has been 
found to be involved in de novo mitochondrial synthesis in various tissues, including the 
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liver and brain (Uldry et al., 2006).  Genetic data has shown that polymorphisms in PGC-
1α have been commonly found in patients with early onset and severe PD (Clark et al., 
2011).  Other members of this gene family, PGC-1β (Kamei et al., 2003) and PRC (PGC-
1-related-cofactor) (Andersson & Scarpulla, 2001), have been shown to maintain some 
functional homology with PGC-1α.  A comparison of the proteins translated from these 
genes shows close similarity and conservation of active sites (Gershman et al., 2007), 
making it difficult to completely study the loss of function in human cells. 
 PGC-1α shares a functional pathway with two previously characterized PD genes: 
PINK1 and Parkin (Ventura-Clapier et al., 2008).  Parkin is a component of a multi-
protein E3 ubiquitin ligase that leads to the ubiquitination and subsequent destruction of 
cellular proteins (Narendra et al., 2008).  Mutations to the Parkin gene result in the 
degeneration of dopaminergic (DA) neurons, most likely by allowing the aggregation of 
multiple dysfunctional mitochondria that eventually lead to overall cell death (Greene et 
al., 2003).  PINK1 (PTEN induced putative kinase 1) is a serine / threonine-protein kinase 
that acts by recruiting Parkin to damaged mitochondria (Koh & Chung, 2011).  Similar to 
mutations in Parkin, mutations in PINK1 lead to degeneration and dysfunction of 
dopaminergic neurons (Yang et al., 2006).  Parkin and PINK1 act together in concert 
along with mitofusin 2 (Mfn2) to remove any damaged or dysfunctional mitochondria that 
may be present, while PGC-1α activity regulates the creation of new mitochondria to 
replace damaged or removed organelles (Chen & Dorn, 2013).  Mutation to any of the 
components of this pathway can lead to impaired mitochondria, decreased cellular fitness 
and eventual cell death. 
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 A single PGC family gene homologue, spargel (srl), has been identified in 
Drosophila melanogaster.   The SRL protein has been characterized as a downstream 
component of the insulin signaling TOR pathway, srl mutant flies have a “lean” 
phenotype, typical of mutations that affect growth and proliferation and reduced 
mitochondrial fitness (Tiefenbock et al., 2009).  Although ubiquitous overexpression of 
srl has been found to negatively impact organism survival, tissue specific srl expression 
has been found to provide beneficial effects.  Overexpression of srl has been shown to be 
sufficient to increase mitochondrial activity and mediate tissue specific lifespan extension 
in the digestive tract and intestine (Rera et al., 2011).  Altered expression of srl in the 
heart has been shown to increase capacity for exercise based endurance improvement, 
while decreased srl in cardiac muscle decreases the locomotor and endurance ability of 
flies (Tinkerhess et al., 2012).  The lack of gene redundancy present in D. melanogaster 
makes it an ideal model system to determine the effects of reduced or increase levels of 
srl expression on whole organism and neuronal longevity, leading to a new model of PD 
for use in future therapeutic studies. 
2.2. Materials and Methods 
2.2.1. Drosophila Media 
The standard cornmeal-yeast-molasses-agar medium is made with 65 g/L cornmeal, 10 
g/L nutritional yeast and 5.5 g/L agar supplemented with 50 ml/L Crosby’s fancy grade 
molasses and 5 ml of 0.1 g/ml methyl 4-hydroxybenzoate in 95% ethanol and 2.5 ml of 
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propionic acid in standard plastic shell vials.  The medium is stored at 4 to 6°C and 
warmed to room temperature for use. 
2.2.2. Drosophila Transgenic Lines 
To express transgenes in a subset of cells, including the dopaminergic neurons, the Ddc-
Gal4HL4.3D line was the generous gift of Dr. Jay Hirsh (University of Virginia) (Lin et al., 
2000).  The following lines were obtained from the Bloomington Drosophila Stock 
Center (at Indiana University-Bloomington): 1) to drive expression behind the 
morphogenetic furrow in the developing eye disc glass multiple reporter-Gal412 (GMR-
Gal4; (Freeman, 1996)); 2) to act as a benign control for the ectopic expression of 
transgenes UAS-lacZ4-2-1 (UAS-lacZ; (Brand & Perrimon, 1993)) ; 3) to express in the 
presence of Gal4 the endogenous srl gene product a line bearing an EPgy2 insertion in the 
5 prime flanking region of srl: y w; P{EPgy2srlEY05931 (UAS- srlEY05931) and 4) to, in the 
presence of Gal4,  express a dsRNA for RNA inhibition (RNAi) of srl: y sc v; 
P{TRiP.HMS00857}attP2 (UAS-srlHMS00857) and y sc v; P{TRiP.HMS00858}attP2 (UAS-
srlHMS00858). 
2.2.3. Scanning Electron Microscopy of Drosophila melanogaster Eye 
Female virgins of the GMR-Gal4 were mated with UAS-lacZ, UAS- srlEY05931, UAS-
srlHMS00857 and UAS-srlHMS00858 males. Male progeny of each cross were collected, aged 
for 3 to 5 days and frozen at -80oC.  Flies were mounted under a dissecting microscope, 
and desiccated overnight. The eyes of mounted flies were imaged via scanning electron 
micrograph at 130 times magnification with a Mineral Liberation Analyzer 650F 
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scanning electron microscope. Total bristle count, and total ommatidia count were 
obtained using ImageJ (Schneider et al., 2012). 
2.2.4. Ageing Analysis  
Female virgins of the Ddc-Gal4 line were mated with UAS-lacZ, UAS- srlEY05931 and 
UAS-srlHMS00858 males. Male progeny of each cross were collected, maintained in cohorts 
of no more than 20 to avoid crowding, and were placed on new medium every two or four 
days for the duration of the experiment. Flies were scored for viability every two days 
until all flies in all genotypes perished.  Survival curves were compared by the log-rank 
(Mantel Cox) test. 
2.2.5. Locomotor Analysis 
From each of the crosses described above, 50 male progeny were collected and 
maintained in vials of 10 flies, and transferred to new medium twice weekly throughout 
the duration of the experiment. One week (seven days) after collection, and in 7-day 
intervals, five cohorts of flies for each genotype were assessed for climbing ability as 
previously described (Todd & Staveley, 2008) . Flies were scored every 7 days for their 
ability to climb within a glass tube of 1.5 cm diameter. Ten trials of each cohort of ten or 
less flies were scored based upon 2 cm intervals of height reached. A climbing index was 
calculated for each vial by the equation:  Climbing Index = ∑ nm / N. Where n is the 
number of flies at a given level, m is the score for that level (1-5), and N is the total 
number of flies climbed for that trial. A nonlinear regression curve of 95% confidence 
intervals was used to analyze graphs of 5 – climbing index as a function of time in days 
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for each genotype. The rate (k) and Y-intercept (Yo) of each non-linear regression curve 
were calculated, where slope represents the rate of decline in climbing ability, and the Y-
intercept represents the initial climbing ability (in the form of 5 – climbing index). As 
neither the slope nor the Y-intercept remained constant across all groups, it was necessary 
that both parameters were incorporated into statistical analysis to determine differences in 
climbing ability.  A comparison of fits concluded whether or not curves differed between 
groups. 
2.3. Results 
A multiple alignment of the SRL protein with the three mammalian homologues; 
PGC-1α, PGC-1β and PRC, provides evidence of evolutionarily conserved protein 
structure between the human and D. melanogaster forms of this gene (Figure 3).  These 
proteins differ in length from 1664 amino acids in the case of PRC, to 798 amino acids 
for PGC-1α.  However, functional domains remain consistent across all four.  Each 
contains an N terminal proline rich domain, a bipartite nuclear localization signal, C 
terminal serine rich region and a highly conserved RNA recognition motif as well as an 
arginine rich region in all except PGC-1β (Figure 3).  Each of the mammalian proteins 
contain at least one leucine rich motif (LXXLL) that can interact with nuclear receptors 
(Matsuda et al., 2004). This motif is not found in srl, however, an alternative leucine rich 
motif (FEALLL) is present which has been shown to also interact with nuclear receptors 
and serve the same function in D. melanogaster (Wang et al., 2007).  The similarities 
between D. melanogaster and mammalian proteins indicate that SRL is an ideal candidate  
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Figure 3: The PGC mammalian family and the Drosophila melanogaster protein SRL share conserved 
protein domains.  A) Aligned sequences show the position of each domain in one D. melanogaster and 
three human PGC family protein sequences.  Light upward diagonal indicates proline rich region, wide 
downward diagonal indicates serine rich region, dark vertical indicates RNA recognition region, solid black 
box indicates nuclear localization sequence, black frame indicates arginine rich region, LXXLL and 
FEALLL indicate leucine rich nuclear recognition motifs.   B) A multiple alignment between PGC-1α, 
PGC-1β, PRC and SRL shows a high degree of sequence conservation within the RNA recognition motif 
found at the carboxyl terminal of each protein.  Domains were identified using ScanProsite (De Castro, 
2006), alignment was done using ClustalW2 (Larkin, 2007).  Protein sequences obtained from UniProt, 
accession numbers [Uniprot NP_037393 (PGC-1α)], [Uniprot NP_573570 (PGC-1β)], [Uniprot NP_055877 
(PRC)] and [Uniprot NP_730835 (SRL)]. Elements of this figure were adapted from Scarpulla et. al. 
(Scarpulla, 2011).   
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to study PGC family activity while avoiding the functional redundancy found in 
other systems.  
 In order to assay the effect of altered srl activity in neurons, we induced 
expression of three constructs previously used by Mukherjee and Duttaroy (Mukherjee & 
Duttaroy, 2013): srl-RNAi (UAS-srlHMS00857), srl-RNAi (UAS-srlHMS00858) and a srl-EY 
(UAS- srlEY05931) in the neuron rich D. melanogaster eye.  Eyes develop two separate yet 
equally important tissues which can be assayed for neuronal loss during development: 
ommatidia and bristles.  At 25°C and 29°C (the latter for increased expression) under the 
direction of GMR-Gal4, expression of both srl-RNAi transgenes decreases the number of 
ommatidia and bristles present in the eye (Figure 4). Tissue specific expression of srl-EY 
results in a slight decrease in number of ommatidia and bristles at 25°C and an increase in 
number of ommatidia and bristles at 29°C.  Similarly, UAS-lacZ under the control of 
GMR-Gal4 shows a slight rough eye phenotype at 29°C (Whitworth, 2011) which is not 
produced by the expression of srl-EY.   
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Figure 4: Tissue specific srl expression in the Drosophila melanogaster eye results in a reduction in 
both ommatidia and bristle number.  A) Scanning electron micrographs of D. melanogaster eyes taken at 
a horizontal field width of 500 µm.  Genotypes are as follows: I) GMR-Gal4 / UAS-lacZ 25oC, II) GMR-
Gal4 / srl-RNAi 1 (UAS-srlHMS00857) 25oC, III) GMR-Gal4 / srl-RNAi 2 (UAS-srlHMS00858) 25oC, IV) GMR–
Gal4 / srl-EY (UAS- srlEY05931) 25oC, V) GMR-Gal4 / UAS-lacZ 29oC, VI) GMR-Gal4 / srl-RNAi 1 (UAS-
srlHMS00857) 29oC.  Images were taken with a FEI MLA 650.  B) Flies show a decrease in the mean number 
of ommatidia present when srl-RNAi 1 (UAS-srlHMS00857) and srl-RNAi 2 (UAS-srlHMS00858) are driven with 
the GMR-Gal4 driver in both standard conditions (25oC) and at a higher temperature (29oC).  Flies show a 
slight but not significant decrease in ommatidia number when srl-EY is expressed in a tissue specific 
manner (UAS- srlEY05931) in both standard conditions (25oC) and at a higher temperature (29oC).  C) Flies 
show a strong decrease in bristle number in standard conditions (25oC) when srl-RNAi 1 (UAS-srlHMS00857), 
srl-RNAi 2 (UAS-srlHMS00858) and srl-EY (UAS- srlEY05931) are expressed in D. melanogaster eyes.  At a 
higher temperature (29oC) srl-EY causes an increase in number of bristles formed compared to lacZ 
controls, however, this is not statistically significant (UAS-lacZ).  Comparisons between LacZ and altered 
gene conditions were measured using a one-way ANOVA and significance was tested using a Tukey post-
hoc test, n=10 flies per genotype.  *P<0.05, **P<0.01, ***P<0.001.  Statistical values may be found in 
supplemental table S1.1. 
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 To determine if the phenotype caused by altered srl expression found in the eye is 
conserved in all neurons we next looked at tissue specific expression of srl in the DA 
neurons. To assay the effect of altered srl activity in DA neurons, we conditionally 
expressed a srl-RNAi transgene (UAS-srlHMS00857) and a tissue specific srl-EY construct 
under the control of the Ddc-Gal4 driver. srl-RNAi expression leads to a significant 
increase in median lifespan with a trending premature loss of climbing ability over time 
when compared to the UAS-lacZ controls (Figure 5).  Tissue specific expression of srl-EY 
lead to both a decrease in lifespan and locomotor climbing.  The data found in the eye and 
DA neuron of D. melanogaster were not identical and indicates that srl expression may 
be very tissue dependent and small changes in certain tissues may lead to differential 
effects.   
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Figure 5: Tissue specific altered srl expression in dopaminergic neurons can lead to a model of 
Parkinson disease Drosophila melanogaster.  A) Expression of srl-RNAi (UAS-srlHMS00858) driven by Ddc-
Gal4 results in an increase in lifespan compared to UAS-lacZ controls.  Dopaminergic srl-EY (UAS- 
srlEY05931) expression resulted in a decrease in lifespan compared to UAS-lacZ controls.  Longevity is shown 
as a percent survival (P<0.05 as determined by the Mantel-Cox Log Rank test) N= >200).  B) Expression of 
srl-RNAi (UAS-srlHMS00858) and srl-EY (UAS- srlEY05931) driven by Ddc-Gal4 cause a decrease in climbing 
ability over time.  Dopaminergic specific expression of srl-EY causes a more severe decrease, however, srl-
RNAi expressing flies live longer and climb slightly worse than UAS-lacZ controls indicating a potential 
decrease in climbing activity compared to lifespan.  Climbing ability was determined via nonlinear curve fit 
(CI=95%).  Error bars indicate standard error of the mean, n = 50.  C) Expression of srl-RNAi (UAS-
srlHMS00858) driven by Ddc-Gal4HL4.3D at 29oC results in an increase in lifespan while srl-EY (UAS- srlEY05931) 
expression at 29oC resulted in a decrease in lifespan compared to UAS-lacZ controls.  Longevity is shown 
as a percent survival (P<0.0001 as determined by the Mantel-Cox Log Rank test) N=>150).  Statistical 
values may be found in supplemental table S1.2. (aging) and S1.3. (climbing). 
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2.4. Discussion 
 PGC-1α has been identified as a modulator of mitochondrial biogenesis, energy 
metabolism (Liang & Ward, 2006), insulin signaling (Pagel-Langenickel et al., 2008) and 
is believed to be implicated in the pathogenesis of human ailments including Alzheimer 
(Qin et al., 2009), Huntington (Cui et al., 2006) and Parkinson diseases (Zheng et al., 
2010).  The study of human PGC-1α is complicated by the partial functional redundancy 
of the other PGC family members, PGC-1β and PRC (PGC-1-related-cofactor).  The 
single Drosophila PGC family homologue, srl, has been linked to mitochondrial 
biogenesis and insulin signaling (Mukherjee & Duttaroy, 2013).  We seek to model PGC 
related disease in D. melanogaster through an analysis of srl function.   
The D. melanogaster eye has been used to study potential genes involved in 
neurodegenerative disease due to the neuron rich nature of the developing tissues located 
there as well as the ease of access for phenotypic analysis.  When two srl-RNAi constructs 
are expressed in this tissue, there is a significant reduction in the number of ommatidia 
and bristles formed.  This effect is exacerbated when flies are raised at 29°C, most likely 
caused by an increase in the activity of the Gal4 expression system, although stress 
responses connected to the fly being at higher than ideal temperatures could also cause 
some of the observed differences.  Alternatively, expression of a previously characterized 
srl-EY transgene seems to have no significant effect on ommatidial viability under normal 
physiological conditions (25°C).  At 29°C, the amount of ommatidial degeneration 
increases significantly across all RNAi genotypes.  Interestingly, overexpression of srl-EY 
at 29°C does not cause significant degeneration of ommatidia or bristles as found in the 
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UAS-lacZ control at higher temperatures.  This could indicate that the ommatidial and 
bristle destruction found when lacZ is expressed at 29°C could be rescued by an 
overexpression of srl.  Experiments by Mukherjee and Duttaroy have shown that srl 
overexpression can rescue FoxO mediated eye destruction (Mukherjee & Duttaroy, 2013).  
It is possible that tissue specific expression of srl in the eye may be sufficient to prevent 
physiological stressors from causing aberrant cell formation under these conditions.   
 Surprisingly, expression of srl-RNAi in DA neurons under the control of the Ddc-
Gal4 driver caused a significant increase in the mean lifespan of flies.  Despite the 
increased longevity of these flies, they lose their climbing ability slightly earlier than 
controls.  When considering the increase in lifespan, this indicates that although they live 
longer, they may have severe locomotor defects during the latter part of their life.  
Alternatively, DA expression of the srl-EY transgene under the control of the Ddc-Gal4 
driver showed a significant decrease in lifespan compared to UAS-lacZ controls.  The 
locomotor and climbing ability of these flies was also decreased.  Taken together, the 
premature mortality and decreased climbing ability displayed in flies expressing srl-EY in 
dopamine decarboxylase neurons appears to give a new, previously uncharacterized, 
model of PD in D. melanogaster. 
 Altered srl expression has been found to cause various phenotypes in a tissue 
specific manner.  Ubiquitous overexpression of srl has been shown to moderately reduce 
mean lifespan while overexpression in intestinal stem cells and cells of the digestive tract 
caused increased lifespan (Rera et al., 2011).  Similarly, increased srl expression in 
cardiac muscle has been linked to exercise based endurance improvement and 
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cardiovascular performance (Tinkerhess et al., 2012).  These findings lead us to believe 
that altered srl expression does not react the same way in the eye model of 
neurodegeneration as in DA neurons.   
 Although an increase in lifespan caused by the expression of srl-RNAi was an 
unexpected result, we hypothesize that a strong decrease in srl expression causes an 
amount of mitochondrial stress sufficient to activate a protein stress response which has 
been shown to increase lifespan (Houtkooper et al., 2013).  The exact mechanism of this 
increase is a topic of much debate with the most popular hypothesis involving an 
activation of the unfolded protein response (UTP) (Haynes & Ron, 2010).  However, it 
has recently been found that in Caenorhabditis elegans, many of the genes involved in 
the UTP are non-essential for this increase in longevity, suggesting another mechanism 
for the increase in organismal longevity (Bennett et al., 2014).  Alternatively, this 
increase in longevity may involve the concept of stress causing the formation of reactive 
oxygen species (ROS) at a low level which provoke cellular anti-oxidants, causing a 
stronger response to future ROS exposure (Lopez-Torres & Barja, 2008).  The most 
commonly used term for this is mitochondrial hormesis (or mitohormesis) (Ristow & 
Zarse, 2010).  It is quite plausible that stress causes increased longevity through a 
combination of factors involving ideas from both of the aforementioned explanations. 
The use of a model organism in identifying and characterizing the pathways of disease 
progression is a fundamental step in creating new and novel treatment options.  Studying 
the consequences of altered srl expression in D. melanogaster allows us to study the 
complex mammalian PGC gene family in a system containing only a single homologue.  
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Identifying the role of srl will lead to an understanding of the associations and pathways 
related to proper function of this gene and subsequently the consequences of improper 
gene function.  Currently, there is no preventative treatment available for PD, and only 
limited options are available to combat advanced symptoms.  Identification of this new 
model of PD provides a framework for more advanced studies into complex gene 
interactions.  Connecting cellular processes and characterizing genetic pathways of 
disease progression may eventually allow for the preventative treatment of genetic forms 
of PD and novel therapeutic options. 
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Chapter 3 – The FBXO7 homologue nutcracker and binding partner 
PI31 in Drosophila melanogaster models of Parkinson Disease 
3.1. Introduction 
 Parkinson Disease (PD) is a progressive neurodegenerative disorder caused by 
decline of function and eventual destruction of dopamine-producing neurons in the brain.  
Symptoms include resting tremor, rigidity, postural instability, bradykinesia and general 
loss of muscle control, as well as cognitive impairment at later stages of disease 
progression (Williams-Gray et al., 2006; Wirdefeldt et al., 2011).  Dopamine is an 
essential neurotransmitter and destruction of neurons that produce dopamine in the 
substantia nigra pars compacta leads to a decreased amount of dopamine being present 
across the striatum of the brain and a subsequent decrease in dopamine-dependent signal 
transduction (Obeso et al., 2008).  This neuronal degeneration may be caused by a 
number of different factors, including dysfunction of molecular machinery relating to the 
removal and overturn of damaged or impaired proteins, increased mitochondrial stress 
resulting in a release of reactive oxygen species, and impaired cellular movement and 
kinetics (Hauser & Hastings, 2013; Imai & Lu, 2011; Shastry, 2003).  The most 
successful pharmacological approaches to PD seek to slow progression of the disease or 
abrogate symptoms by replacing available dopamine in the brain.  To date, no treatment 
seeking to abrogate disease symptoms has been successful. 
For the most part, Parkinson Disease has been viewed as an age-related sporadic 
condition, but severe early onset cases of PD have been identified and found to be linked 
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to mutations in specific genes.  Initially, it was believed that these inherited forms of 
disease were independent anomalies, but many of these cases share similar methods of 
disease progression (Chung et al., 2001).  One of the most common underlying causes for 
cellular destruction in PD is a breakdown or partial loss of function in proteasomal 
machinery (Matsuda & Tanaka, 2010; McNaught et al., 2006).  Proteasomal systems 
within cells are responsible for protein turnover and removal of potentially harmful 
unwanted cellular components.  Ubiquitin mediated proteolysis is an ATP-dependent, 
multi-step process by which this protein turnover occurs.  The first step tags the target 
protein with ubiquitin acting as a marker for termination.  Next, the 26S proteasome 
degrades the targeted protein.  Finally, the components of this proteasome system and the 
short peptide fragments of the targeted protein are recycled (Lecker et al., 2006).  The 
coordinated effort of three enzymes allows this system to properly function.  The first, E1 
or activating enzyme, functions as a ubiquitin carrier.  The second, E2 or conjugating 
enzyme, accepts this ubiquitin molecule from the E1 enzyme and presents it to the final 
enzyme, E3.  This ligating enzyme is responsible for specific attachment of the ubiquitin 
molecule to the target of interest (Neutzner & Neutzner, 2012).  Of the three enzymes, the 
E3 ligating enzymes are the most diverse.  This allows for a high degree of target 
specificity and a cascade of activity stemming from a few general E1 activators to dozens 
of E2 conjugators and hundreds of E3 ligators (Pickart & Rose, 1985).  Improper function 
of any component in this system may lead to harmful consequences and a potentially 
deadly build-up of dysfunctional proteins.     
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Evidence of a severe form of inherited PD has been found that results in cellular 
dysfunction and breakdown not just in the dopaminergic neurons but also in neurons 
located in other areas of the brain.  This condition has been termed Parkinsonian-
pyramidal syndrome (PPS) and has been described to result in a severe and precocious 
form of disease (Rajendran et al., 2000).  Like traditional models of PD, PPS acts by 
damaging neurons in specific areas of the mid-brain to cause movement dysfunction and, 
eventually, cognitive decline.  Unlike traditional models of PD, PPS affects neurons in the 
pyramidal area of the brain, leading to direct loss of muscle control and symptoms that 
present earlier than other forms of PD (Lai et al., 2012).  Mutation of the FBXO7 gene 
has been implicated as a causative factor in the pathology of this extreme form of PD (Di 
Fonzo et al., 2009).  Although specific mutations have been isolated that lead to this 
disease phenotype, the mechanisms behind this system and why these mutations lead to a 
parkinsonian phenotype have yet to be determined. 
FBXO7 encodes the F-box only protein 7 (also known as Park15), a component of 
Skp-Cullin1-Fbox (SCF) E3 ligases (Hsu et al., 2004).  These complexes mediate the 
attachment of ubiquitin to proteins in the cell either for modified function in the case of 
single attachment at lysine-63 (Zeng et al., 2009), or to mark targets for degradation by 
the 26S proteasomal machinery via polyubiquitination of lysine-48 (Chau et al., 1989).  
Within the SCF complex, F-box proteins provide target specificity, allowing the 
regulation of essential cellular processes such as differentiation, DNA quality control, 
circadian rhythm and neuronal synapse formation (Merzetti et al., 2013).  Evidence of 
intracellular proteinaceous inclusions in FBXO7 forms of PPS suggest that breakdown of 
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the proteasomal machinery may be a direct result of mutation in this gene (Zhao et al., 
2013).  A decrease in the concentration of FBXO7 protein in neuronal cells correlates 
with an onset of PD phenotypes through a mechanism with Parkin (Burchell et al., 2013).   
Structurally, FBXO7 contains an F-box motif (residues 329-375) which interacts with 
Skp1 (Cenciarelli et al., 1999).  Interaction with the E2-ubiquitin conjugating enzyme 
occurs at the N-terminal ubiquitin-like domain.  The specificity of this protein comes 
from a proline-rich region (PRR) at the C-terminal.  Substrates of the SCF complex bind 
to this C-terminal PRR to hasten ubiquitination (Chang et al., 2006).  FBXO7 is 
differentially expressed throughout the brain and recent evidence has shown that FBXO7 
interacts with PARKIN and PINK1 in vivo to mediate proper mitochondrial function 
(Burchell et al., 2013).  Furthermore, FBXO7 is highly expressed in regions of the brain 
associated with PD, including the cerebral cortex, globus pallidus and substantia nigra 
(Nelson et al., 2013).  The function of FBXO7 relies upon stabilization by a binding 
partner.  Originally named for its inhibition of the 20S proteasome (Chu-Ping et al., 
1992), proteasomal-inhibitor-31 (PI31) interacts with FBXO7 through a shared N-
terminal region aptly named the FBXO7/PI31 (FP) domain (Kirk et al., 2008).  Despite 
its original identification as a proteasomal inhibitor, it appears as if PI31 acts as an 
activator of the 26S proteasome through stabilization of the SCF complex.   
D. melanogaster has proven to be a convenient model organism for the study of human 
disease in vivo.  An abundance of genetic tools, access to the complete genome and a 
quick generation time make flies an ideal system to study specific disease linked genes.  
Furthermore, D. melanogaster has been extensively used as a model neurological system 
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due to similar complexity of neurons and neurotransmitter systems compared to higher 
organisms (Bilen & Bonini, 2005).  A putative D. melanogaster homologue of FBXO7 
has been identified by Bader et al (2010).  This gene, termed nutcracker (ntc), shares 
sequence similarity to FBXO7 within the F-box domain and has been shown to function 
in pathways of proteolysis (Bader et al., 2011).  Initially, ntc was implicated to play a role 
in the terminal differentiation of male germ cells, a process that relies heavily upon 
proteasomal machinery (Bader et al., 2010).  Disruption of ntc directly leads to a 
reduction in proteasome activity without reducing proteasomal machinery.  This indicates 
that disruption of the proteolytic cascade likely occurs at protein ubiquitination when ntc 
is dysfunctional, however, protein degradation catalase enzymes could also be 
accountable (Cao et al., 2003).  Thus, ntc seems to play the same role as an E3 ubiquitin 
ligase in D. melanogaster as FBXO7 does in mammals. 
A D. melanogaster homologue of PI31 has been studied as a regulator of ubiquitin 
mediated proteolysis.  In cells where a mutation of PI31 is present, there is a marked 
accumulation of poly-ubiquitinylated proteins, indicating a defective proteasome (Bader 
et al., 2011).  This phenotype can be rescued by moderate overexpression of the wild type 
PI31 protein but a high level of expression or a complete loss of function in PI31 leads to 
lethal phenotypes.  This indicates that PI31 is tightly regulated and important for proper 
cellular function.  Furthermore, cells expressing a mutation in the FP binding domain 
show similar phenotypes to PI31 null mutants (Bader et al., 2011).  Taken together, it is 
clear that PI31 and ntc are necessary regulators of the 26S proteasome in D. 
melanogaster.  In this paper, we investigate the role of both ntc and PI31 in D. 
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melanogaster and determine what role these genes may play in neuron function in this 
model system. 
3.2. Materials and Methods 
3.2.1. Fly Stocks  
The UAS-HA-ntc (UAS-ntc), UAS-PI31RNAi28858 (PI31-RNAi), and UAS-HA-PI31 (UAS-
PI31) stocks were generously provided by Dr. H. Steller of Rockefeller University (Bader 
et al., 2010; Bader et al., 2011). Ddc-Gal4HL4.3D and the Ddc-Gal4HL4.36 were provided by 
Dr. J. Hirsh (University of Virginia). UAS-α-synuclein was provided by Dr. M. Feany 
(Harvard Medical School). The GMR-Gal412 , UAS-lacZ and UAS-ntcRNAi (ntc-RNAi) 
stock were obtained from the Bloomington Drosophila Stock Center at Indiana 
University.  All fly stocks were maintained on standard cornmeal-yeast-molasses-agar at 
25oC. 
3.2.2. Scanning Electron Microscopy of Drosophila melanogaster Eye 
Female virgins of the GMR-Gal412 were mated with UAS-lacZ, ntc-RNAi,UAS-ntc, PI31-
RNAi and UAS-PI31 males. Male progeny of each cross were collected, aged for 3 to 5 
days and frozen at -80oC.  Flies were mounted under a dissecting microscope, and 
desiccated overnight. The eyes of mounted flies were imaged via scanning electron 
micrography at 130 times magnification with a Mineral Liberation Analyzer 650F 
scanning electron microscope.  Ommatidia and bristle counts were performed and 
annotated using ImageJ (Schneider et al., 2012). 
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3.2.3. Ageing Analysis 
Female virgins of Ddc-Gal4HL4.3D, Ddc-Gal4HL4.36 and UAS-asyn;Ddc-Gal4HL4.36 
genotypes were collected every 12 hours for several days. These virgins were placed in 
vials with males of genotypes UAS-lacZ, UAS-ntc, UAS-PI31, ntc-RNAi and PI31-RNAi.  
Male progeny of each cross were collected over 18 days until at least 250 flies for each 
genotype were obtained. Progeny were maintained in vials of 20 flies maximum and were 
scored for viability every second day beginning two days after collection. Flies were 
placed on new food twice weekly and after a death event for the duration of the 
experiment. Ageing analysis continued every second day until all flies in all genotypes 
were deceased.  Survival curves were compared by the log-rank (Mantel Cox) test 
performed by Graph Pad Prism Statistical Software. 
3.2.4. Locomotor Analysis 
Female virgins of Ddc-Gal4HL4.3D, Ddc-Gal4HL4.36 and UAS-asyn;Ddc-Gal4HL4.36 
genotypes were collected every 12 hours for several days. These virgins were placed in 
vials with males of genotypes UAS-lacZ, UAS-ntc, UAS-PI31, ntc-RNAi and PI31-RNAi.  
Fifty male progeny of each cross were collected and maintained in vials of 10 flies, and 
were placed on new food twice weekly throughout the duration of the experiment. One 
weeks after collection and each week thereafter, flies were assessed for climbing ability. 
Flies were scored for their ability to climb a 30 cm glass tube of 1.5 cm diameter. Ten 
flies were given 10 seconds to climb and were scored based on the height reached.  The 
outside of this glass vial was labelled with 5 lines, each 2 cm apart with each space 
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between lines acting as a score from 1 (under 2cm) to 5 (over 8cm). 10 trials were 
performed for each vial of 10 flies. A climbing index was calculated for each vial by the 
equation:   
Climbing Index = ∑ nm / N 
where n is the number of flies at a given level, m is the score for that level (1-5), and N is 
the total number of flies climbed for that trial. A non-linear regression curve of 95% 
confidence intervals was used to analyze graphs of 5 – climbing index as a function of 
time in days for each genotype. The rate (k) and Y-intercept (Y0) of each non-linear 
regression curve were calculated, where slope represents the rate of decline in climbing 
ability, and the Y-intercept represents the initial climbing ability (in the form of 5 – 
climbing index). As neither the slope nor the Y-intercept remained constant across all 
groups, it was necessary that both parameters were incorporated into statistical analysis to 
determine differences in climbing ability.  A comparison of fits concluded whether there 
was a significant difference between data groups.  This assay and subsequent statistical 
analysis has been developed previously by Stavely and Haywood (2004). 
3.3. Results 
A National Centre for Biotechnology Information basis local alignment search 
tool (BLAST) search using the Homo sapiens FBXO7 protein as a query returns ntc as a 
match at 27% identical.  Closer analysis of the specific protein domains in both the 
FBXO7 and NTC proteins shows a much higher degree of conservation in the active 
regions of the proteins (Figure 6).   Although NTC is smaller than FBXO7 (314 versus 
522 amino acids in length), both proteins retain PI31 and F-box binding regions (Figure 
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6A).  Retention of these domains indicates similar evolutionarily conserved functions for 
both proteins in distantly related organisms.  The H. sapiens and D. melanogaster forms 
of the PI31 protein are 30% identical, similar in size (271 versus 270 amino acids), and 
they retain the C-terminal proteasome binding region and N-terminal F-box binding 
domains found to be functionally important in human cell culture (Figure 6B) (Kirk et al., 
2008; Li et al., 2014).  The high degree of similarity and conserved domain structure 
found between H. sapiens and D. melanogaster proteins allows the possibility that NTC 
and PI31 may be D. melanogaster homologues of their prospective human proteins.  
To determine the consequence of altered ntc expression in neuronal tissue, we directed 
the expression of the transgenes UAS-ntc and ntc-RNAi in the D. melanogaster eye.  Eyes 
develop two distinct yet equally important neuronal tissues: ommatidia and inter-
ommatidial bristles.  Assaying developmental defects in these tissues gives a good 
indication of the consequences in other neurons affected by similar alteration in gene 
activity.  To manipulate gene activity, we used a GMR-Gal412 transgene in combination 
with the responder transgenes and carried out this experiment at both 25°C and 29°C; the 
latter is typically utilized to produce a greater level of activity due to the Gal4-UAS 
system’s increased performance at higher temperatures.     
Tissue specific expression of the UAS-ntc transgene caused a similar and 
significant decrease in the number of ommatidia and bristles at 25°C. Interestingly, no 
significant difference in tissue number was found in either bristles or ommatidia at 29°C 
(Figure 7A).  It is possible that altered ntc expression has a negative effect on the cell up 
until a certain threshold is reached and then is no longer able to elicit a response.   
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Figure 6: The mammalian FBXO7 and PI31 proteins share conserved protein domains with putative 
Drosophila melanogaster homologues nutcracker and PI31.  A) Aligned protein sequences show the 
domains conserved between FBXO7 and NTC.  Wide upward diagonal indicates PI31 binding domain, dark 
downward diagonal indicates F-box domain.  B) Human and D. melanogaster PI31 show highly conserved 
protein size and domains.  Light horizontal indicates the C-terminal proteasome complex binding region; 
light vertical indicates N-terminal FBXO binding region.  Protein sequences obtained from UniProt, 
accession numbers [Uniprot NP_036311 (FBXO7)], [Uniprot NP_ 647829.1 (ntc)], [Uniprot NP_848693.2 
(PI31)] and [Uniprot NP_ (D. melanogaster PI31)].  Alignment may be found in supplemental figure S2.1. 
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Figure 7: Tissue specific expression of ntc in the Drosophila melanogaster eye leads to a decrease in 
ommatidia and bristle numbers.  A) Scanning electron micrographs of D. melanogaster eyes taken at a 
horizontal field width of 500 µm.  Genotypes are as follows: I) GMR-Gal412 / UAS-lacZ (25°C), II) GMR–
Gal412 / UAS-lacZ (29°C), III) GMR-Gal412 / UAS-ntc (25°C), IV) GMR-Gal412 / UAS-ntc (29°C), V) GMR–
Gal412 / ntc-RNAi (25°C), VI) GMR–Gal412 / ntc-RNAi (29°C).  B) Flies show a decrease in the overall 
number of ommatidia when ntc and ntc-RNAi transgenes are directed by GMR-Gal412.  Expression of the 
ntc transgene appears to have a similar effect on tissue formation at both 25°C and 29°C while the ntc-RNAi 
transgene results in a severe decrease in ommatidia number at 29°C. C) Expression of ntc and ntc-RNAi 
transgenes causes a similar significant decrease in bristle formation when directed by GMR-Gal4 at 25°C.  
When the expression is enhanced at 29°C, both transgenes show an increase in tissue disruption compared 
to lacZ controls.  Comparisons were between 25°C controls and experimental flues and 29°C controls and 
experimental flies and measured using a one-way ANOVA and significance was tested using a Tukey post-
hoc test, n=10.  *P<0.05, **P<0.01, ***P<0.001.  Statistical values may be found in supplemental table 
S2.2. 
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Alternatively, it is possible that the destruction caused by the increase of stress and 
transgene expression system at 29°C is more disruptive then the addition of ntc.  Tissue 
specific expression of ntc-RNAi caused a significant decrease in both ommatidia and 
bristle numbers at 25°C and a similar, yet more severe, rough eye phenotype at 29°C.   
Expression of PI31 in the D. melanogaster eye caused a significant decrease in the 
number of ommatidia formed compared to lacZ controls at 29°C (Figure 8A).  This effect 
was not found at 25°C.  The expression of ntc-RNAi caused a decrease in bristle number 
at both 25°C and a significant more severe decrease at 29°C.  This effect is found at 29°C 
in ommatidia but once again not a consequence of expression at 25°C in this tissue.  This 
may indicate that PI31 is more tightly regulated in the D. melanogaster eye, especially at 
higher levels of expression, than ntc but ommatidia seem to be less susceptible to altered 
expression levels until high levels of expression exist. 
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Figure 8: Altered PI31 expression can lead to a rough eye phenotype in Drosophila melanogaster.  A) 
Scanning electron micrographs of D. melanogaster eyes taken at a horizontal field width of 500 µm.  
Genotypes are as follows: I) GMR-Gal412 / UAS-lacZ (25°C), II) GMR–Gal412 / UAS-lacZ (29°C), III) 
GMR-Gal412 / UAS-PI31 (25°C), IV) GMR-Gal412 / UAS-PI31 (29°C), V) GMR–Gal412 / PI31-RNAi (25°C), 
VI) GMR–Gal412 / PI31-RNAi (29°C).  B) Tissue specific expression of PI31 and PI31-RNAi transgenes in 
the D. melanogaster eye cause a small yet significant decrease in ommatidia number at 25°C and a severe 
decrease in ommatidia with increased GMR-Gal412 activity at 29°C. C) Bristle formation is severely 
disrupted when PI31 and PI31-RNAi transgenes are directed by Gal4 at both 25°C and 29°C, with the 
expression of PI31-RNAi at 29°C resulting in a severe rough eye phenotype.  Comparisons were between 
25°C controls and experimental flues and 29°C controls and experimental flies and measured using a one-
way ANOVA and significance was tested using a Tukey post-hoc test, n=10.  *P<0.05, **P<0.01, 
***P<0.001.  Statistical values may be found in supplemental table S2.2. 
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Figure 9: Expression of ntc, ntc-RNAi, PI31 and PI31-RNAi in the dopaminergic neurons of 
Drosophila melanogaster reduces mean lifespan.  A) Tissue specific expression of ntc-RNAi and ntc 
cause a significant decrease in mean lifespan when driven in the dopaminergic neurons by Ddc-Gal4HL4.3D.  
Expression of a UAS-ntc transgene causes a more severe decrease in mean lifespan compared to wild type 
UAS-lacZ controls. B) These trends are also observed when a separate driver, Ddc-Gal4HL4.36, is used to 
provide dopaminergic specific expression.  C, D) PI31 and PI31-RNAi expression in dopaminergic neurons 
causes a slight yet significant decrease in mean lifespan compared to lacZ controls with both Ddc-
Gal4HL4.3D and Ddc-Gal4HL4.36 drivers.  Longevity is shown as a percent survival (P<0.05 as determined by 
the Mantel-Cox Log Rank test), N=>200.  Statistical values may be found in supplemental table S2.3. 
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To determine if the negative effects associated with altered ntc and PI31 
expression in the eye are conserved in other neuronal tissues, we next altered gene 
activity in the dopaminergic neurons. Dopaminergic expression of ntc-RNAi under the 
control of the transgenic insertions Ddc-Gal4HL4.36 and Ddc-Gal4 HL4.3D led to significant 
decreases in lifespan compared to the lacZ controls (Figure 9A and 9B).  Expression of 
UAS-ntc under the control of Ddc-Gal4HL4.36 lead to a similar significant decrease in mean 
lifespan compared to lacZ controls (Figure 4B).  Altered ntc activity in the dopaminergic 
neurons has a severe negative effect on the mean lifespan of D. melanogaster.   
Expression of either PI31 or PI31-RNAi in the dopaminergic neurons under the 
control of Ddc-Gal4HL4.36 or Ddc-Gal4 HL4.3D resulted in a significant decrease in the mean 
lifespan of flies compared to lacZ controls (Figure 9C and 9D).  Although this decrease in 
lifespan was not as severe as witnessed in the case of altered ntc expression, flies with 
altered PI31 expression still failed to live as long as the control group.  This indicates that 
PI31 may be tightly regulated in dopaminergic neurons and a change in expression leads 
to decreased lifespan in D. melanogaster.          
Ectopic expression of human α-synuclein in D. melanogaster has been shown to 
produce disease-modelling phenotypes, including impaired locomotor function and tissue 
disruption (Feany & Bender, 2000). Altered activity of ntc or PI31, along with α-
synuclein in the dopaminergic neurons, was assayed to investigate the potential to 
influence these phenotypes.  
Dopaminergic expression of a ntc-RNAi construct significantly increased median 
lifespan compared to a lacZ control in an α-synuclein background (Figure 10A).  This  
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Figure 10: Expression of ntc-RNAi in an α–synuclein background rescues the observed decrease in 
median lifespan associated with a Parkinson Disease model.  A) Tissue specific expression of ntc-RNAi 
in an α–synuclein background increases the mean lifespan of flies compared to UAS-lacZ;α -synuclein 
controls.   B) Despite this increase in lifespan, the locomotor activity of flies expressing the ntc-RNAi 
construct is decreased compared to controls.  C) UAS-PI31 expression had no significant effect on the mean 
lifespan of flies in an α–synuclein background but PI31-RNAi construct expression causes a severe and 
significant decrease in mean lifespan compared to UAS-lacZ;α–synuclein controls.  D) The locomotor 
ability of UAS-PI31 expressing flies is not significantly different from controls but PI31-RNAi expressing 
flies climb slightly better than UAS-lacZ;α –synuclein controls.  Longevity is shown as a percent survival 
(P<0.05 as determined by the Mantel-Cox Log Rank test), N=>200. Climbing ability was determined via 
nonlinear curve fit (CI=95%).  Error bars indicate standard error of the mean, n = 50.  Statistical values may 
be found in supplemental table S2.4. (Aging) and S2.5. (Climbing). 
  
  
75 
 
indicates that expression of ntc-RNAi in an α-synuclein background has a positive effect 
in dopaminergic neurons.  Despite this increase in mean lifespan, however, locomotor 
climbing assays indicate that there is no significant difference in time between when ntc-
RNAi; α-synuclein and lacZ ; α-synuclein flies lose their climbing ability (Figure 10B).  
This indicates that although the mean lifespan of ntc-RNAi flies is longer in a PD 
background, the motor ability of these organisms may be compromised earlier in overall 
lifespan than in lacZ controls.  
Dopaminergic PI31-RNAi expression in an α-synuclein background led to a severe 
and significant decrease in longevity compared to lacZ controls (Figure 10C).  Flies 
expressing both α-synuclein and PI31-RNAi lived only about 60% as long as α-synuclein 
and lacZ expressing controls.  Expression of PI31 caused no significant difference in 
mean lifespan compared to a lacZ control.  Additionally, there was no significant 
difference in the locomotor climbing ability of flies expressing both PI31 and PI31-RNAi 
in an α-synuclein background (Figure 10D). 
3.4. Discussion 
Mammalian FBXO7 functions as an E3 ubiquitin ligase, which is the targeting 
sub-unit of a multi-component proteasomal system responsible for recognizing and 
destroying damaged or dysfunctional proteins in the cell.  Mutations in FBXO7 have been 
identified as the cause of a particularly severe form of PD (Lai et al., 2012).  A putative 
homologue of FBXO7, nutcracker, has been identified in D. melanogaster.  We have 
attempted to characterize the consequences of altered expression of this putative 
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homologue in the neuron rich eye and in dopaminergic neurons on organism development 
and locomotor control.   
Expression of a UAS-ntc transgene in the D. melanogaster eye led to a significant 
decrease in the number of ommatidia and bristles compared to lacZ controls at 25°C.  
Although the number of bristles continued to decrease significantly between 25°C and 
29°C, the number of ommatidia remained constant across both temperatures.  The largest 
discrepancy in this data is that no significant different in ommatidia or bristles was 
observed when ntc was overexpressed at 29°C.  This indicates that ntc may be an 
important regulator of neuronal function but after a certain amount of this protein is 
absent the cell is able to adapt and prevent further destruction by alternative means.  The 
E3 ubiquitin ligase proteins MuRF1 and FBXO32 (ATROGIN in D. melanogaster) have 
been shown to be rate limiting factors in cardiac muscle (Baumgarten et al., 2013; Kedar 
et al., 2004), thus it is possible that increased ntc expression has a negative effect on 
neuronal tissue formation until a certain threshold of expression is reached upon which 
time ntc it no longer the rate limiting factor in proteasome activity.  It is also possible that 
the effect of ntc overexpression on the eye is less severe than the destruction associated 
with general transgene expression in the eye at this temperature (29°C).   
Eye specific expression of ntc-RNAi leads to a significant decrease in both the 
number of ommatidia and bristles in the D. melanogaster eye compared to lacZ controls.  
Unlike the ntc overexpression phenotypes, this tissue disruption resulted in significantly 
less ommatidia and bristles at 29°C and 25°C.  This indicates that expression of ntc-RNAi 
in the eye directly influences the viability of the eye tissues and causes more severe 
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defects.  Given that ntc is a necessary component for proper proteasome function, altered 
gene activity by the expression of an RNAi likely results in more aberrant protein 
accumulation within the cell and eventually cell death, leading to the observed phenotype 
of eye disruption.  The increased severity of this phenotype with increased expression in 
the 29°C eye supports this observation.  Altered expression of ntc both by UAS-ntc and 
ntc-RNAi lead to similar phenotypes, indicating that proper SCF proteasome complex 
function is imperative to overall cell health.  An increase of ntc may lead to over 
stimulation of this complex, causing off target ubiquitin mediated destruction while a 
decrease in ntc expression may lead to harmful protein accumulations within the cell, 
eventually leading to premature cell mortality. 
Altered dopaminergic expression of ntc caused by both UAS-ntc and ntc-RNAi led 
to a decrease in mean lifespan compared to lacZ controls.  This decrease was significant 
and caused flies to live approximately 66% as long as the control group (mean lifespan of 
40 days versus 60 days).  It would be expected that expression of ntc-RNAi would 
decrease the mean lifespan of flies in relation to a control, since reduced FBXO7 
expression has been shown to reduce lifespan in vertebrate models (Randle et al., 2015).  
Decreased longevity associated with expression of UAS-ntc may be due to an increase in 
proteasome activity, potentially causing non-specific degradation of target proteins.  
Direct interaction of FBXO7 and PARKIN has been found in human cells; this interaction 
has been shown to be important in the process of mitophagy (Burchell et al., 2013).  
FBXO7 and ntc may share a similar role in mammals and D. melanogaster, respectively, 
with regard to neuronal cell function and development.   
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Altered activity of PI31 caused a negative phenotype on the D. melanogaster eye.  
Expression of either a UAS-PI31 or a PI31-RNAi transgene led to developmental defects 
in both the ommatidia and bristles of the eye and reduced longevity when expressed 
directly in dopaminergic neurons.  This effect has been previously characterized in the D. 
melanogaster eye by Bader et. al. (Bader et al., 2011), however, we are the first to look at 
the effect of altered PI31 expression in dopaminergic neurons.  Although PI31 acts as a 
stabilizing protein in the SCF ubiquitin ligase complex, it has also been characterized as a 
direct binding inhibitor of the 20S proteasome complex (Li et al., 2014).  Two separate 
areas of the PI31 protein are responsible for this activity with the C-terminal region 
binding to FBXO7 and the N-terminal region binding to the 20S proteasome (Kirk et al., 
2008).  It is possible that a decrease in the amount of PI31 reduces the efficiency of the 
SCF proteasome complex due to de-stabilization while an increase in PI31 leads to 
inhibition of proteasome machinery via direct binding of extra PI31 to the proteasome 
itself.   
Mutation of the SNCA gene leads to the accumulation of harmful protein 
aggregates of misfolded α-synuclein known as Lewy bodies (Spillantini et al., 1998).  
Although no D. melanogaster homologue of this gene exists, transgene constructs 
expressing α-synuclein in flies have been characterized as effective models of human 
disease pathways (Feany & Bender, 2000).  Ectopic expression of α-synuclein in neurons 
causes tissue defects and premature loss of locomotor ability.  Over expression of parkin 
or Pink1 with ectopic dopaminergic expression of α-synuclein results in a rescue 
phenotype, restoring locomotor ability to wild type levels (Haywood & Staveley, 2004; 
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Todd & Staveley, 2008).   We co-expressed α-synuclein with either ntc or PI31 in 
dopaminergic neurons to determine if the negative phenotype associated with ectopic α-
synuclein expression is rescued or made worse in each case. 
Co-expression of ntc-RNAi and α-synuclein in dopaminergic neurons led to a 
significant increase in lifespan compared to controls.  Despite benefitting from increased 
longevity, flies expressing both ntc-RNAi and α-synuclein lose their climbing ability at the 
same time as α-synuclein-expressing control flies, indicating that although they live 
longer, they suffer from impaired locomotor control.  Decreased ntc activity by the 
expression of ntc-RNAi may lead to lowered activity of the SCF ubiquitin proteasome.  It 
is possible that this diminished proteasome activity could reduce the amount of cell death 
occurring, leaving unhealthy neurons containing intracellular inclusions that could in turn 
cause locomotor defects.  Unhealthy neurons continue to function until a buildup of 
dysfunctional components causes whole cell death but are not eliminated immediately in 
this case which could explain why longevity is increased but climbing ability is not 
significantly different from controls.   Alternatively, a decrease in ntc coupled with the 
presence of intracellular inclusions caused by ectopic α-synuclein expression could lead 
to a protein stress response which has been linked to increased lifespan in flies 
(Houtkooper et al., 2013).  The exact mechanism of this protein response is yet unknown, 
however, it may be triggered by the low level presence of reactive oxygen species, which 
in turn trigger activity of cellular anti-oxidants (Lopez-Torres & Barja, 2008).  The 
increased longevity induced by expression of ntc-RNAi in an α-synuclein background is 
likely caused by a combination of these factors. 
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Co-expression of PI31-RNAi and α-synuclein led to a decrease in mean lifespan, while 
co-expression of PI31 and α-synuclein had no significant effect on the mean lifespan of 
flies when expressed in dopaminergic neurons.  The expression of α-synuclein caused a 
decrease in locomotor activity when expressed alone (Todd & Staveley, 2008), though we 
observed no significant difference in the climbing ability of flies when either PI31 or 
PI31-RNAi were co-expressed. 
Studying the homologues of known genes in a model organism such as D. 
melanogaster is a fundamental step in understanding and characterizing disease onset and 
progression.  FBXO7 has been implicated in a rare and severe form of disease known as 
PPS.  In this paper, we show that expression of the putative D. melanogaster homologue 
of FBXO7, nutcracker, leads to reduced mean lifespan when altered in neuronal cells.  
We have shown that the putative D. melanogaster homologue of the tightly controlled 
mammalian PI31 regulator leads to severe defects when expression is altered in neurons.  
Additionally, we have shown that altered expression of either ntc or PI31 in an α-
synuclein model of PD leads to a different outcome than in a control background.    These 
models of H. sapiens PD in Drosophila melanogaster may be further studied to determine 
pathways of onset which may eventually lead to novel therapeutic treatments for 
combating disease progression. 
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Chapter 4 – Altered expression of a putative FBXO9 homologue models 
Parkinson Disease in Drosophila melanogaster 
4.1. Introduction 
Progressive and continuous loss of function of neurons in specific areas of the 
brain can lead to neurodegenerative disorders such as Parkinson Disease (PD) and 
Alzheimer Disease (AD) (Xie et al., 2014).  Neuronal dysfunction can be caused by 
environmental factors, such as exposure to pesticide and neurotoxic metals, or by the 
inheritance of disease causing alleles of specific genes (Chin-Chan et al., 2015; Johnson, 
1991).  Although either environmental or genetic influences can lead to disease 
independently, in many cases, it is a combination of the genetic risk factors and exposure 
to toxins that can determine the onset of disease (Kalia & Lang, 2015).  The identification 
and characterization of genes responsible for inherited forms of neurodegenerative 
disease may lead to new therapeutic approaches and novel treatments to slow and 
potentially prevent disease progression, regardless of the underlying cause.   
 PD and AD, the two most prevalent human neurodegenerative disorders, may both 
result from the accumulation of proteins into proteinaceous inclusions. A hallmark of PD 
is the presence of Lewy bodies, which are intracellular cytoplasmic inclusions composed 
of mis-folded aggregate clusters of α–synuclein (α–SYN), produced by altered expression 
of the SNCA gene (Olanow & McNaught, 2011).  In the conventional model of AD, the 
presence of TAU inclusions, hyper-phosphorylated deposits of the microtubule stabilizing 
protein TAU, and an over-abundance of the amyloid precursor protein cause premature 
  
85 
 
neuronal death and disease symptoms (Goedert et al., 1995; Wright et al., 1991).  
Although these proteins were originally implicated in the pathogenesis of either PD or 
AD, aberrant activity of α–SYN and Tau products has been determined to be present in 
both conditions (Moussaud et al., 2014).  α–SYN has been implicated in the pathogenesis 
of AD by playing a role in abnormal synapse formation, while high levels of TAU in 
cerebral spinal fluid has been used as a powerful diagnostic tool in pre-screening for PD 
(Kang et al., 2013; Kim et al., 2004).  This suggests that a mechanism of neuronal 
destruction and disease may be somewhat conserved between PD and AD.  Aberrant 
protein clusters, caused by mutant forms of α–SYN and TAU, prevent normal cellular 
function and increase the oxidative stress level of the cell, eventually leading to premature 
mortality (Atkin & Paulson, 2014).  Although the cell is equipped with mechanisms to 
prevent permanent damage associated with aberrant protein function, defects in 
intracellular protein turnover have been associated with neurodegenerative disease.   
 The ubiquitin proteasome system is one of the basic cellular mechanisms devoted 
to the degradation of intracellular components in a tightly regulated and highly specific 
manner (Glickman & Ciechanover, 2002).  This complex selectively targets proteins 
within the cell and adds a single or multiple ubiquitin moieties, which in turn either alters 
the function of the protein or marks it for future destruction by the 26S proteasome (Chau 
et al., 1989; Zeng et al., 2009).  This system works through the activity of three enzymes: 
1) the E1, activating enzyme; 2) the E2 conjugating enzyme; and 3) the E3 ligating 
enzyme (Ciechanover et al., 2000).  Mutation of E3 enzymes has been implicated as a 
cause of disease pathology (Bielskiene et al., 2015).  A sub-class of E3 enzymes contain 
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unique proteins known as F-box proteins.  These proteins contain a conserved F-box 
domain used to bind to the Skp-Cullin complex, creating the Skp-Cullin-F-box (SCF) 
ubiquitin ligase complex (Cardozo & Pagano, 2004).  The SCF ubiquitin ligase complex 
is integral to proper cellular health and protein turnover, with impaired function leading to 
premature cell death and disease phenotypes (Genschik et al., 2013).  Current research 
into new therapeutics has focused on emulating or mimicking the activity of the E3 
components of these complexes to stimulate the removal of harmful proteins in the cell 
(Bulatov & Ciulli, 2015).  The targeting function of the F-box proteins is an essential 
aspect of the SCF ubiquitin ligase complex. 
 In particular, the FBXO group of proteins is of interest to the study of disease, as a 
number of these are involved in essential biological processes and have been implicated 
as causative factors in disease onset and progression.  Two of these FBXO genes have 
been directly implicated in degenerative disorders: FBXO7, also known as PARK15, has 
been shown to be mutated in a severe early onset form of PD known as Parkinsonian-
pyramidal syndrome (Di Fonzo et al., 2009); while FBXO32, or atrogin, has been linked 
to muscle wasting phenotypes (de Palma et al., 2008).  Both FBXO7 and FBXO32 belong 
to the same evolutionary sub-family along with another gene, FBXO9, which is poorly 
characterized (Cenciarelli et al., 1999).  Understanding the role that FBXO9 plays in 
pathways of ubiquitination may lead to a better understanding of various disease 
phenotypes.      
The putative D. melanogaster homologue of FBXO7/nutcracker (ntc) was 
originally identified as a factor in the terminal differentiation of sperm with ntc mutations 
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causing male sterility (Bader et al., 2010).  The highly conserved F-box binding domain 
found in FBXO7 is conserved in ntc.  Altered expression of ntc in both the neuron rich D. 
melanogaster eye and dopaminergic neurons has been found to lead to degenerative, PD-
like phenotypes, mimicking the symptoms observed with altered FBXO7 function in 
Homo sapiens (See Chapter 3).  The high degree of functional conservation between 
FBXO7 in humans and flies suggests that FBXO9 may also have a functional homologue 
in D. melanogaster.  We have attempted to identify and characterize the putative fly 
homologue of FBXO9 and we have determined that altered expression can influence 
development of the eye and reduce longevity when expressed in the dopaminergic 
neurons. 
4.2. Materials and Methods 
4.2.1. Drosophila Media 
The standard cornmeal-yeast-molasses-agar medium is made with 65 g/L cornmeal, 10 
g/L nutritional yeast and 5.5 g/L agar supplemented with 50 ml/L fancy grade molasses 
and 5 ml of 0.1 g/ml methyl 4-hydroxybenzoate in 95% ethanol and 2.5 ml of propionic 
acid in standard plastic vials.  Media is stored at 4°C but warmed to room temperature 
before use.   
4.2.2. Drosophila Transgenic Lines 
The Ddc-Gal4HL4.3D (Ddc-Gal4) line was the generous gift of Dr. Jay Hirsh (University of 
Virginia) (Lin et al., 2000).  The following lines were obtained from the Bloomington 
Drosophila Stock Center at Indiana University-Bloomington: 1) to drive expression 
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behind the morphogenetic furrow in the developing eye disc Glass Multiple Reporter-
Gal412 (GMR-Gal4; (Freeman, 1996)); 2) to act as a control for the ectopic expression of 
transgenes UAS-lacZ4-2-1 (UAS-lacZ; (Brand & Perrimon, 1993)) ; 3) To alter expression 
of CG5961, P{EP}CG5961G4347 (CG5961EP) and P{TRiP.JF01332}attP2 [CG5961-
JF01332](CG5961-RNAi).  
4.2.3. Scanning Electron Microscopy of Drosophila Melanogaster Eyes 
Female virgins of the GMR-Gal4 were mated with UAS-lacZ, CG5961EP and CG5961-
RNAi males. Male progeny of each cross were collected, aged for 3 to 5 days and frozen 
at -80°C.  Flies were mounted to metal stubs and desiccated for 24 hours pre-imaging. 
The eyes of mounted flies were imaged via scanning electron micrography at 130 times 
magnification with a Mineral Liberation Analyzer 650F scanning electron microscope. 
Total bristle count and ommatidia count were obtained using ImageJ (Schneider et al., 
2012). 
4.2.4. Ageing Analysis 
Female virgins of the Ddc-Gal4 line were mated with UAS-lacZ, CG5961EP and CG5961-
RNAi males. Male progeny of each cross were collected each day and placed into separate 
vials of no more than 20 flies.  Vials were scored for survival every 2 days and media was 
changed after each death event or every 3 days.  Survival curves were compared by the 
log-rank (Mantel Cox) test, graphs were created using GraphPad Prism software. 
  
89 
 
4.3. Results 
FBXO9 belongs to a sub-family of genes responsible for target specificity in ubiquitin 
ligase complexes along with the well-established Parkinson gene FBXO7/PARK15.  A 
phylogenetic analysis shows that evolution between the FBXO orthologues is consistent 
among species (Figure 11A).  Despite divergent evolution, functional domains and 
conserved residues are well-maintained between both FBXO9 and FBXO7, suggesting 
important functions for both genes with regard to organism survival.  A bioinformatics 
search (tBLASTn) using human FBXO9 as a query identified a putative D. melanogaster 
homologue, CG5961.  The overall similarity between the two proteins is 33%, however, 
the level of conservation within protein functional domains is greater.  The human 
FBXO9 protein is 437 amino acids in length, while the putative Drosophila protein is 442 
amino acids.  Each of the two proteins shares 4 distinct domains: a microtubule 
interacting and trafficking domain (MIT), a tetratricopeptide repeat sequence (TRS), an 
F-box domain and a c-terminal nuclear localization sequence (NLS) (Figure 12B).  Of 
these domains, the highest degree of similarity is in the F-box domain that spans 51 
amino acids in length with 33 absolutely conserved amino acid residues and 12 well-
conserved functionally similar amino acid residues (Figure 12C).  However, human 
FBXO9 contains an HNH nuclease family domain (Jin et al., 2004) that we were unable 
to identify in the D. melanogaster protein. The high degree of similarity between 
conserved active domains suggests that CG5961 is the D. melanogaster homologue of 
FBXO9.      
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Figure 11: Alignment of the human FBXO9 and Drosophila melanogaster CG5961 proteins shows a 
high degree of conservation.  A) FBXO7 and FBXO9 are highly conserved among vertebrates and 
invertebrates. B) Both human and D. melanogaster FBXO9 proteins contain similar microtubule interacting 
and trafficking domains(dark horizontal), tetratricopeptide repeat (no fill), and F-box domains (dark 
vertical) and have a similar protein length of 437 amino acids and 442 amino acids respectively.  Each 
protein also contains a nuclear localization sequence (wide upward diagonal) at the carboxyl-terminal end.  
C) Alignment of the protein sequence of the F-box domain between D. melanogaster and human FBXO9 
shows a high degree of similarity.  Dark grey indicates a perfect match; light grey indicates substitution of 
an amino acid with similar function.  Domains were identified using ScanProsite (De Castro E, 2006), Pfam 
(Finn et al., 2014) and NLS mapper (Kosugi et al., 2009) alignment generated by ClustalW2 (Larkin MA, 
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2007), cladogram created using maximum parsimony method and bootstrapped 5000 times using MEGA6 
(Tamura et al., 2013).  Protein sequences were obtained from UniProt, ascension numbers [NP_258441] 
Homo sapiens FBXO9, [NP_036311] Homo sapiens FBXO7, [NP_001074959] Mus musculus FBXO9, 
[NP_694875] Mus musculus FBXO7, [NP_956012] Danio rerio FBXO9, [NP_001020670] Danio rerio 
FBXO7, [NP_650206] Drosophila melanogaster CG5961, [AAF47792] Drosophila melanogaster ntc, 
[XP_308962.3] Anopheles gambiae FBXO9, [XP_565383] Anopheles gambiae FBXO7.  Alignment may 
be found in supplemental figure 3.1. 
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Figure 12: Altered tissue specific expression of CG5961 in the Drosophila melanogaster eye causes a 
decrease in ommatidia and bristle number. A) Scanning electron micrographs of D. melanogaster eyes 
taken at a horizontal field width of 500 µm.  Genotypes are as follows: I) GMR-Gal4 / UAS-lacZ 25°C; II) 
GMR–Gal4 / UAS-lacZ 29°C; III) GMR-Gal4 / CG5961EP 25°C; IV) GMR-Gal4 / CG5961EP 29°C; V) 
GMR–Gal4 / CG5961-RNAi 25°C; VI) GMR–Gal4 / CG5961-RNAi 29°C.  Images were taken with a FEI 
MLA 650.  B) The D. melanogaster eye shows a decrease in number of ommatidia and bristles when either 
CG5961EP or a CG5961-RNAi transgene is under the control of GMR-Gal4.  This decrease in tissue 
formation is more severe at the elevated temperature of 29°C likely due to the increased efficiency of the 
Gal4-UAS system.  Comparisons were made between 25°C control and experimental flies and 29°C control 
and experimental flies and measured using a one-way ANOVA and significance was tested using a Tukey 
post-hoc test, n=10.  *P<0.05, **P<0.01, ***P<0.001.  Statistical values may be found in supplemental 
table S3.2. 
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The D. melanogaster eye has been used to determine the neurodevelopmental 
effects of gene alteration since both ommatidia and bristles, the two main tissues 
composing the eye, are of neuronal origin (Cook et al., 2011).  To determine the broad 
scale neuronal implications of altered CG5961 activity, we directed the expression of 
CG5961 (via CG5961EP) and the inhibition of CG5961 (via a CG5961-RNAi transgene), 
using the GMR-Gal4 transgene in the developing D. melanogaster eye.  These 
experiments were conducted at both at 25oC and 29oC, the former acting as the standard 
physiological condition and the latter to elevate the activity of Gal4-UAS system 
expression.  Tissue specific expression of CG5961 caused a significant decrease in both 
ommatidia and bristle number compared to lacZ controls at 25°C (Figure 12).  Directed 
inhibition through the expression of the CG5961-RNAi construct caused a similar loss in 
ommatidia and bristle number as expression of CG5961 did compared to lacZ controls at 
25°C but this effect was not seen at 29°C.  It would appear as though CG5961 has a 
purpose in the neurons composing the D. melanogaster eye and changes to expression 
have a significant negative effect at 25°C, however, this effect is not observed at 29°C 
and no significant effect on eye formation is observed.   
 To determine the effect of altered CG5961 expression in neuronal cells directly 
linked to neurodegenerative disease, both CG5961EP and CG5961-RNAi transgenes were 
expressed in the dopaminergic neurons under the control of the Ddc-Gal4 transgene.  
Dopaminergic specific expression of CG5961EP caused a significant decrease in mean 
lifespan compared to lacZ controls (Figure 3).  Fifty percent of the CG5961EP flies died 
by day 48, while the control lacZ flies did not reach 50 percent survival until day 60.  
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This is a significant decrease in lifespan of approximately twenty percent.  Expression of 
CG5961-RNAi in dopaminergic neurons caused a decrease in longevity (44 days) 
compared to lacZ controls of approximately twenty-five percent (Figure 13).  This 
decrease was slightly more severe than seen with the expression of CG5961EP and 
indicates that in dopaminergic neurons, much like the D. melanogaster eye, CG5961 is 
tightly regulated and altered expression of this gene causes severe negative consequences.   
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Figure 13: Tissue specific expression of both CG5961 and CG5961-RNAi causes a decrease in 
longevity similar to established models of Parkinson Disease in Drosophila melanogaster.  Expression 
of CG5961 under the control of Ddc-Gal4 causes a significant decrease in lifespan (Ddc-Gal4; CG5961EP: 
median 48 days) compared to lacZ controls (Ddc-Gal4; UAS-lacZ: median 60 days).  Similarly, expression 
of a CG5961-RNAi transgene under the control of Ddc-Gal4 causes a greater loss in longevity (Ddc-Gal4; 
CG5961-RNAi: median 44 days).  (P<0.0001 as determined by the Mantel-Cox Log Rank test) N=>200).  
Statistical values may be found in supplemental table S3.3. 
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4.4. Discussion 
 The four protein domains conserved between human FBXO9 and the putative D. 
melanogaster homologue provide some insight into the function of this gene.  The highly 
conserved F-box domain is found in each of the D. melanogaster homologues of the 
FBXO family of F-box proteins including FBXO7 and FBXO32 and has been determined 
to be responsible for mediating the protein-protein interaction between the F-box protein 
and the SCF ubiquitin ligase complex (Cardozo & Pagano, 2004). The microtubule 
interacting and trafficking (MIT) domain has been implicated in endosomal trafficking 
and microtubule movement (Ciccarelli et al., 2003).   Current knowledge of MIT domains 
focuses on the endosomal trafficking ATPase Vps4, which becomes activated by the 
direct binding of an additional protein termed the MIT-interacting motif (Hurley & Yang, 
2008).  The tetratricopeptide repeat (TPR) domain is a 34 amino acid sequence motif 
found in a number of diverse proteins responsible for forming scaffolds for protein-
protein interactions (Blatch & Lassle, 1999).  The structure of the TPR closely resembles 
that of the MIT and both suggest a role in protein-protein interaction within the cell, a 
role suited to the targeting function associated with other FBXO proteins.  The nuclear 
localization sequence tags a protein for import into the nucleus and suggests that the 
activity of FBXO9 may be localized to that location (Marfori et al., 2011).  Taken 
together, the presence of these conserved domains indicates that human FBXO9 and the 
putative homologue CG5961 likely both function as components of a multi-component 
SCF ubiquitin ligase complex.   
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 The ommatidia and bristles of the D. melanogaster eye are formed from neuronal 
precursors and allow for highly sensitive characterization of mutations that alter neural 
developmental function (Sang & Jackson, 2005).  Specific altered expression of CG5961 
in the neuron rich D. melanogaster eye leads to the disruption of tissue formation and a 
decrease in both ommatidia and bristle number.  Expression of CG5961 appears to be 
highly regulated in the neurons of the eye and deviation of this expression leads to severe 
phenotypes.  Although there has been no previous investigation into the effects of altered 
CG5961 expression in the D. melanogaster eye, CG5961 appears to be essential and 
necessary for proper neuronal cell development. 
 Dopaminergic neurons produce dopamine, a neurotransmitter necessary for motor 
control.  Impaired dopamine production through the improper functioning of these 
neurons leads to severe defects and premature mortality.  To determine if the observed 
negative phenotype associated with driven expression of CG5961 in the eye was 
conserved in neuronal tissues, we evaluated the effects of altered expression in 
dopaminergic neurons to determine what, if any, consequence it would have on overall 
lifespan in D. melanogaster.  Directed dopaminergic expression of either CG5961 or 
CG5961-RNAi led to a significant decrease in overall lifespan compared to lacZ controls.  
This decrease in lifespan indicates that CG5961 is essential in the proper function of 
dopaminergic neurons.  Furthermore, it appears as if CG5961 may be regulated in a 
highly controlled manner, however, the nature of this regulation remains unknown.  
Mutation of both FBXO7 and FBXO32 have been linked to human disease phenotypes, 
with altered expression of FBXO7 causing a PD like phenotype in D. melanogaster (See 
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Chapter 3).  The decrease in longevity found when CG5961 is altered in dopaminergic 
neurons suggests the possibility of a link between the human FBXO9 gene and human 
degenerative disease. 
 The FBXO family of genes have been implicated in a number of inherited genetic 
disorders.  Although FBXO7 and FBXO32 have been identified to participate in the 
processes of neurodegeneration and muscular degeneration respectively, a closely related 
gene, FBXO9, has not been well characterized.  We show the D. melanogaster CG5961 
gene has a high degree of similarity to Homo sapiens FBXO9 and that altered expression 
of this gene leads to degenerative phenotypes in both the eye and dopaminergic neurons 
of flies.  This is the first evidence of a potential link between FBXO9 and degenerative 
disease phenotypes and shows that the putative D. melanogaster homologue of FBXO9 
may be an important gene in neuronal development and function.  Further research into 
the pathways and interacting proteins involved in pathways of FBXO9 mediated 
proteolytic activity may lead to new targets for disease prevention and therapeutic 
strategy.   
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Chapter 5 – Identification and evaluation of potential PARIS 
homologues in Drosophila melanogaster  
5.1. Introduction 
Parkinson Disease (PD) is the second most common neurodegenerative disorder, 
affecting more than 1.6% of individuals over 65 years of age, with an associated annual 
healthcare cost of an estimated $25 billion US dollars (as reported in 2011) (Beitz, 2014).  
PD patients present with symptoms related to impaired motor control including 
bradykinesia, postural rigidity and resting tremor plus, in later stages, diminished 
cognitive function including dementia and memory loss (Klockgether, 2004).  The former 
symptoms are well known to occur as a direct result of lost neurons in the substantia 
nigra pars compacta region of the brain, leading to a decrease in the available 
neurotransmitter dopamine.  Efforts to combat PD have focused on symptom alleviation 
and fail to prevent progression or stem the initial onset of disease.  PD may be caused by 
inherited or environmental factors and in many cases a combination of genetic risk 
factors, and exposure to harsh environmental conditions such as toxins combine to lead to 
symptoms of disease (Mitsui, 2013).  Many genes implicated in PD onset have function 
either related to or directly linked to the proper maintenance and upkeep of mitochondria.  
Mitochondria are the site of oxidative phosphorylation and produce much of the energy 
for a given cell; impaired function of these organelles in neurons with high energy 
requirements may be the origin of premature mortality and disease onset found in PD 
(Ryan et al., 2015).  The intracellular balance of mitochondria is an essential part of 
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proper cell function and changes to this balance can result in a number of negative 
consequences.  In the event of mitochondrial damage, impaired organelles are repaired or 
removed and recycled into usable components.  If removal is necessary, a separate 
process initiates the formation of new mitochondria to restore the energetic capacity of 
the cell (Palikaras & Tavernarakis, 2014).  Mutation to genes involved in either of these 
processes can cause a loss of cellular energy and eventual cell mortality.  Identifying and 
characterizing the genes responsible for mitochondrial impairment in PD may lead to new 
therapeutic targets and novel options in disease management. 
Parkin and PTEN-induced putative kinase 1 (Pink1) are two genes that function in 
the normal turnover of damaged or dysfunctional mitochondria and prevent the 
accumulation of potentially toxic impaired organelles (Eiyama & Okamoto, 2015).  
Parkin encodes an E3 ubiquitin ligase that leads to the ubiquitination and subsequent 
destruction of cellular proteins (Narendra et al., 2008).  Mutations to the Parkin gene 
result in the degeneration of dopaminergic (DA) neurons, most likely by allowing the 
aggregation of multiple dysfunctional mitochondria that eventually lead to overall cell 
death (Greene et al., 2003).  PINK1 is a serine / threonine-protein kinase that acts by 
recruiting PARKIN to damaged mitochondria (Koh & Chung, 2011).  Similarly, 
mutations to PINK1 lead to degeneration and dysfunction of DA neurons (Yang et al., 
2006).  Under normal physiological conditions, mitochondria prevent the outer membrane 
accumulation of the PINK1 protein. When the mitochondria becomes depolarized this no 
longer occurs, allowing a build-up of PINK1 at the mitochondria which then recruits the 
Parkin gene product (PARKIN) and begins the cascade of ubiquitin mediated organelle 
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destruction (Eiyama & Okamoto, 2015).  Mutations in Pink1 or Parkin have been directly 
linked to early onset forms of human PD. 
The Parkin mediated removal of impaired mitochondria leads to an overall 
decrease in number of cell organelles, this mitochondrial deficit is corrected by a parallel 
pathway involving the peroxisome proliferation activated co-receptor (PGC) family of 
genes (Scarpulla, 2011).  The three members of this gene family, PGC-1α, PGC-1β and 
PGC-1 related cofactor (PRC) all share similar and partially redundant function in 
mitochondrial biogenesis.  PRC has been implicated to be present mostly in proliferating 
cells while PGC-1α and PGC-1β are both found in tissues with high energetic 
requirements such as skeletal muscle (Gleyzer & Scarpulla, 2011; Rowe et al., 2012; 
Russell et al., 2005).  Although PGC-1α and PGC-1β are expressed in the same tissues 
and have been linked to the regulation of exercise endurance, PGC-1α has specifically 
been found to be induced by stimuli including stress, exercise and fasting (Lehman et al., 
2000; Watson et al., 2007).  Under normal physiological conditions, the PGC-1α gene is 
repressed by the negative regulatory protein PARIS (Parkin Interacting Substrate) (Shin 
et al., 2011).  The PARIS protein in Homo sapiens is coded for by the ZNF746 gene 
(herein referred to simply as PARIS) and has been shown to be localized to neurons, 
including those of the substantial nigra pars compacta (Shin et al., 2011).  
Overexpression of PARIS in a mouse model resulted in destruction of dopaminergic 
neurons which could be rescued with the overexpression of either Parkin or PGC-1α 
(Shin et al., 2011).  It appears that Parkin may act as a master regulator keeping the 
balance between mitochondrial removal and biogenesis and ensuring the cell receives an 
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appropriate amount of energy for normal function.  Subsequently, altered expression of 
downstream components, including PARIS and PGC-1α, lead to disease phenotypes in 
otherwise healthy organisms.   
 Drosophila melanogaster has been used as a model organism of human disease 
research with great success.  Similarities between the nervous system of Drosophila and 
Homo sapiens allow for complex study of neurodegenerative disorders (Sang & Jackson, 
2005; West et al., 2015).  The neuron rich Drosophila eye is an ideal system to study the 
broad effect of genetic mutation on neuronal tissue, providing a highly sensitive array of 
ommatidia and bristle tissues that respond and are altered by any negative change to 
neuron cell architecture (Mishra & Knust, 2013).  Many genes, including Parkin and 
Pink1, implicated in PD pathology have functional D. melanogaster homologues and 
show severe neuronal dysfunction when expression is altered (Clark et al., 2006; 
Haywood & Staveley, 2004).  Unlike the three PGC family members present in humans, 
D. melanogaster have only a single PGC-1α homologue, spargel (srl) (Tiefenbock et al., 
2010).  Previous research has indicated that altered srl expression may lead to 
parkinsonian phenotypes in D. melanogaster, providing a powerful model to study the 
complex interactions behind disease progression (Merzetti & Staveley, 2015).  The 
conserved activity of gene homologues for Parkin, PGC-1α and Pink1 shows that 
pathways of mitochondrial upkeep and biogenesis are highly conserved across organisms.  
Despite this, the only H. sapiens gene found to act upon the Parkin/Pink1 pathway 
without a putative D. melanogaster homologue is PARIS. We seek to identify potential 
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PARIS candidates in D. melanogaster and to characterize these candidates in neuron 
tissues to determine their potential role in pathways of disease. 
5.2. Materials and Methods 
5.2.1. Drosophila Culture 
The Ddc-Gal4HL4.3D (Ddc-Gal4) line was the gift of Dr. Jay Hirsh (University of Virginia) 
(Lin et al., 2000).  The following lines were obtained from the Bloomington Drosophila 
Stock Center at Indiana University-Bloomington: 1) to drive expression behind the 
morphogenetic furrow in the developing eye disc glass multiple reporter-Gal412 (GMR-
Gal4; (Freeman, 1996)); 2) to act as a control for the ectopic expression of transgenes 
UAS-lacZ4-2-1 (UAS-lacZ; (Brand & Perrimon, 1993)); 3) to express spargel (srl): y w; 
P{EPgy2srlEY05931}5.2.2(srl-EY) and 4) to inhibit the expression of srl: y sc v; 
P{TRiP.HMS00858}attP2 (UAS-srlHMS00858) (UAS-srl-RNAi).  RNAi transgenes for 
putative PARIS homologues were obtained from the Vienna Drosophila Resource Center 
stock numbers 7779 UAS-Crol-RNAi, 43655 (UAS-CG15269-RNAi) and 39986 (UAS-
CG15436-RNAi) (Dietzl et al., 2007).   
 
The standard cornmeal-yeast-molasses-agar medium is made with 65 g/L cornmeal, 10 
g/L nutritional yeast and 5.5 g/L agar supplemented with 50 ml/L fancy grade molasses 
and 5 ml of 0.1 g/ml methyl 4-hydroxybenzoate in 95% ethanol and 2.5 ml of propionic 
acid in standard plastic vials.  All media was stored at 4°C and warmed to room 
temperature for use as required. 
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5.2.2. Scanning Electron Microscopy of the Drosophila melanogaster Eye 
Female virgins of the GMR-Gal4 line were mated with UAS-lacZ, UAS-Crol-RNAi, UAS-
CG15269-RNAi, UAS-CG15436-RNAi, UAS-srl-EY and UAS-srl-RNAi males. Male 
progeny of each cross were collected, stored in vials of no more than 20 flies, aged 3-5 
days and frozen at  
-80°C.  Flies were mounted to metal stubs and desiccated for 24-48 hours pre-imaging. 
The eyes of mounted flies were imaged via scanning electron micrograph at 130 times 
magnification with a Mineral Liberation Analyzer 650F scanning electron microscope. 
Total bristle count, and ommatidia count were obtained using ImageJ (Schneider et al., 
2012). 
5.2.3. Ageing Analysis 
Female virgins of the Ddc-Gal4 line were mated with UAS-lacZ, UAS-Crol-RNAi, UAS-
CG15269-RNAi and UAS-CG15436-RNAi males. Male progeny of each cross were 
collected in vials of no more than 20 flies.  Vials were scored for survival every 2 days 
and media was changed after each death event or every 3 days.  Survival curves were 
compared by the log-rank (Mantel Cox) test, graphs were created using GraphPad Prism 
software. 
5.3. Results 
The H. sapiens PARIS gene encodes a protein of a predicted 645 amino acids with 
identified homologues in chimpanzee, rhesus monkey, cow, mouse and rat.  A detailed 
bioinformatics analysis of PARIS shows the presence of an N-terminal Kruppel  
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Figure 14: The Homo sapiens PARIS protein shares conserved protein domains with putative 
Drosophila melanogaster homologues Crol, CG15269 and CG15436.  A) Aligned protein sequences show 
the position of protein domains in three putative D. melanogaster homologues of PARIS.  Wide downward 
diagonal indicates KRAB domain, wide upward diagonal indicated ZAD domain and narrow vertical box 
indicates zinc-finger double binding domains.  B) Alignment of the zinc-finger double binding domain in 
the Homo sapiens PARIS and D. melanogaster CG15436 proteins shows a high degree of amino acid 
conservation.  Dark grey indicates same amino acid; light grey indicates an amino acids of similar function.  
Domains were identified using ScanProsite (De Castro E, 2006), and Pfam (Finn et al., 2014) alignment 
generated by ClustalW2 (Larkin MA, 2007).  Protein sequences were obtained from UniProt, ascension 
numbers NP_001156946.1 (PARIS), NP_477243.1 (CROL), NP_609739.2 (CG15269 and NP_608840.1 
(CG15436).  Alignment and annotation of proteins may be found in supplementary figure S4.1.  
  
109 
 
Associated Box (KRAB) domain and two C-terminal zinc-finger double domains (Figure 
1).  KRAB domains are transcriptional repressors found in C2H2 zinc finger proteins.  
These functional modules comprise the largest group of transcriptional regulators in 
mammals and are limited to the tetrapod superclass of organisms (Urrutia, 2003).  Despite 
the significance of this gene in regulation of mitochondrial biogenesis and cellular energy 
production, currently there are no known PARIS homologues identified in non-
mammalian lineages.  The PARIS protein was used as a query to identify potential D. 
melanogaster homologues using NCBI Blast (Altschul et al., 1990).  Of the proteins, the 
three top identified candidates were crooked legs (CROL) with 35% identity, CG15436 
with 33% identity and CG15269 with 29% identity to the PARIS H. sapiens protein.  The 
overall protein structure of these putative homologues were compared to the PARIS 
protein to determine potential conserved domains (Figure 14).  CG15436, CG15269 and 
CROL all contain C-terminal zinc-finger double domains similar to those found in the 
PARIS protein (Figure 14A).  CROL is a protein composed of 962 amino acids and has 
activity as a negative regulatory factor involved in proper limb development.  CG15269 
encodes a predicted protein of 587 amino acids with no identified function.  The activity 
of CROL and presence of zinc finger motifs in CG15269 would suggest that it may also 
function as a negative transcriptional repressor.  In addition to the zinc finger motifs 
found in all three putative homologues, CG15436 contains a specialized N-terminal zinc-
finger domain known as a zinc associated domain (ZAD).  ZAD domains have been 
theorized to act in a similar fashion to KRAB domains and are thought to be the D. 
melanogaster equivalent of this domain (Jauch et al., 2003).  Alignment of the N-terminal 
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KRAB domain of PARIS and ZAD domain of CG15436 shows a high degree of protein 
sequence similarity with 51 amino acids, either identical or of similar function over a 75 
amino acid span.  CG15436 is a 346 amino acid long protein that has not yet been 
characterized.  Due to the presence of multiple zinc-finger domains, it is believed that the 
activity of this protein is related to transcriptional regulation.  Although little is known 
about this protein, a single homologue has been identified in Xenopus tropicalis(Altschul 
et al., 1990).  Based on the presence of both N-terminal C2H2 zinc-finger domains and 
the C-terminal ZAD domain, CG15436 appears to be the most PARIS-like gene identified 
by our bioinformatics analysis.   
The adult D. melanogaster eye is composed of two separate yet equally important 
tissues: ommatidia and bristles.  The formation of these tissues stems from neuronal 
precursors, and they can easily be imaged and quantified using a scanning electron 
microscope, making the eye a highly sensitive system for determining the effect of altered 
gene expression in neurons.  We expressed RNAi transgene lines of the three putative 
PARIS candidates driven by GMR-Gal4 to determine the consequence of reduced gene 
function (Figure 15).  Eye specific expression of the CG15269-RNAi construct resulted in 
a slight, yet significant, loss of ommatidia at 25°C.  This effect was exacerbated at 29°C, 
a temperature used to increase the amount of driven transgene expression as  
higher temperatures increase the efficiency of the Gal4-UAS system, indicating that 
further expression of CG15269-RNAi caused further tissue destruction.  Expression of the 
Crol-RNAi construct caused a severe decrease in both ommatidia and bristle formation at  
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Figure 15: Expression of Crol-RNAi and CG15269-RNAi transgenes causes a decrease in both ommatidia and 
bristle count in the Drosophila melanogaster eye.  A) Scanning electron micrographs of D. melanogaster eyes taken 
at a horizontal field width of 500µm.  Genotypes are as follows: I) GMR-Gal4 / UAS-lacZ 25oC, II) GMR-Gal4 / Crol-
RNAi 25oC, III) GMR-Gal4 / CG15269-RNAi 25oC, IV) GMR-Gal4 / CG15436-RNAi 25oC, V) GMR–Gal4 / UAS-lacZ 
29oC VI) GMR–Gal4 / Crol-RNAi 29oC, VII) GMR-Gal4 / CG15269-RNAi 29oC, VIII) GMR-Gal4 / CG15436-RNAi 
29oC.  Flies show a decrease in the number of ommatidia and bristles present when Crol-RNAi and CG15269-RNAi 
transgenes are expressed at 25oC.  This effect intensifies at 29oC causing a further decrease in tissue number for both 
transgenes with Crol-RNAi being more severe in both cases.  Expression of a CG15436-RNAi has no effect on 
ommatidia and bristle number at 25oC and only a shows only a slight decrease in tissue number at 29oC.  All counts 
compared to a UAS-lacZ control of the same temperature, comparisons were measured using a one-way ANOVA and 
significance was tested using a Tukey post-hoc test, n=10.  Images were taken with a FEI MLA 650 Scanning Electron 
Microscope.  *P<0.05, **P<0.01, ***P<0.001.  Statistical values may be found in supplemental table S4.2. 
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Figure 16: Expression of srl-EY and CG15436 transgenes show a similar phenotype while expression of a srl-
RNAi line causes a severe decrease in ommatidia and bristle number in the Drosophila melanogaster eye.  A) 
Scanning electron micrographs of D. melanogaster eyes taken at a horizontal field width of 500µm.  Genotypes are as 
follows: I) GMR-Gal4 / UAS-lacZ 25oC, II) GMR-Gal4 / Crol-RNAi 25oC, III) GMR-Gal4 / CG15269-RNAi 25oC, IV) 
GMR-Gal4 / CG15436-RNAi 25oC, V) GMR–Gal4 / UAS-lacZ 29oC VI) GMR–Gal4 / Crol-RNAi 29oC, VII) GMR-
Gal4 / CG15269-RNAi 29oC, VIII) GMR-Gal4 / CG15436-RNAi 29oC.  Flies show a decrease in both ommatidia and 
bristle count with a srl-RNAi transgene is expressed at both 25oC and 29oC.  Expression of srl-EY causes no effect on 
ommatidia count and a slight decrease in bristle count at 25oC and a slight decrease in both ommatidia and bristle count 
at 29oC.  Similarly, there is no effect on the eye when a CG15436 transgene is expressed at 25oC and a slight decrease 
in both ommatidia and bristle count at 29oC.  All counts compared to a UAS-lacZ control of the same temperature, 
comparisons were measured using a one-way ANOVA and significance was tested using a Tukey post-hoc test, n=10.  
Images were taken with a FEI MLA 650 Scanning Electron Microscope.  *P<0.05, **P<0.01, ***P<0.001.  Statistical 
values may be found in supplemental table S4.4 
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25°C compared to a UAS-lacZ control, and a severe loss of both bristles and ommatidia at 
29°C.  
  To determine if one of the three candidate PARIS genes is acting in pathways 
related to srl function, we looked at the effect of altered srl expression in the D. 
melanogaster eye.  Driven expression of a srl-EY transgene construct causes a slight 
decrease in ommatidia number at both 25°C and 29°C, and a slight decrease in bristle 
count at 29°C compared to a UAS-lacZ control (Figure 16).  There was no decrease in 
bristle number at 25°C.  Expression of a srl-RNAi transgene caused a sharp and severe 
decrease in both ommatidia and bristle number at both 25°C and 29°C.  In comparison,  
expression of a CG15436-RNAi transgene caused no change in ommatidia and bristle 
number at 25°C or 29°C.  Expression of both a srl-EY and CG15436-RNAi transgene 
seem to cause similar effects when driven by a GMR-Gal4 driver in the D. melanogaster 
eye. 
Dopaminergic neurons are essential producers of dopamine and altered expression 
of genes implicated in neurodegenerative disease in these neurons leads to a decrease in 
mean lifespan compared to controls.  This results in an ideal system to identify potential 
causative disease genes by assaying the tissue specific consequences of altered gene 
expression in these dopaminergic neurons. To determine the effect of altered putative 
PARIS homologue expression in dopaminergic neurons, the Ddc-Gal4 transgene was used  
to direct the inhibition of the three candidate genes via RNAi.  Tissue specific expression 
of Crol-RNAi in dopaminergic neurons resulted in a significant decrease in mean lifespan 
(56 days) compared to UAS-lacZ controls (60 days) while the directed expression of a 
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CG15436-RNAi transgene resulted in a significant increase in mean lifespan (64 days) 
(Figure 17).  Expression of a CG15269 transgene did not result in a significant difference 
in mean lifespan (62 days) compared to the UAS-lacZ controls.  
  
  
115 
 
 
 
Figure 17: Dopaminergic expression of a CG15436-RNAi transgene increases while expression of a 
Crol-RNAi transgene decreases mean lifespan in Drosophila melanogaster.  Altered expression of Crol 
in the dopaminergic neurons by expression of a Crol-RNAi transgene causes a significant decrease in mean 
longevity compared to UAS-lacZ controls.  CG15436 seems to have an opposite effect as expression of a 
CG15436-RNAi transgene causes a significant increase in lifespan compared to UAS-lacZ controls.  
CG15269-RNAi expression has no significant effect on mean lifespan when expressed in dopaminergic 
neurons.  All transgene lines driven by the Ddc(II)-Gal4 driver, longevity is shown as a percent survival 
(P<0.05 as determined by the Mantel-Cox Log Rank test) N= >150).  Statistical values may be found in 
supplemental table S4.4. 
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5.4. Discussion 
 Beginning with the sequence of the H. sapiens PARIS protein, bioinformatics 
analysis has led to the identification of three similar genes with the potential to be the D. 
melanogaster homologue(s). Two of these genes, CG15269 and CG15436, have not been 
investigated to any great extent except that they have been characterized as encoding 
zinc-finger containing proteins.  The third gene, crooked-legs (Crol), has been identified 
to encode a transcription factor involved in leg morphogenesis and as a mediator of cell 
cycle progression that has been studied as a potential interacting factor in models of 
Huntington Disease (D'Avino & Thummel, 1998; Kaltenbach et al., 2007; Mitchell et al., 
2008).  Although Crol has been implicated in models of human disease, little to no 
analysis of the effect upon a range of neuronal tissues has been performed.  Interestingly, 
the KRAB motif, as found in the H. sapiens PARIS gene product, is a highly conserved 
motif found in over one third of all mammalian zinc-finger transcription factors (Urrutia, 
2003).  The KRAB domain is not well conserved in D. melanogaster zinc-finger 
transcription factors, although a domain with similar function and composition exists: 
ZAD (Chung et al., 2002).  The presence of this domain in only one of the three putative 
D. melanogaster homologues suggests that CG15436 may be the most likely PARIS 
candidate.  In addition to this N-terminal ZAD domain, CG15436 contains two C-
terminal zinc-finger double domains, similar to that found in the human PARIS gene 
product.  This domain is important in protein-protein binding interactions and, although 
some KRAB domain proteins exist without the C-terminal zing-finger domains, these 
proteins have been found to function in the sequestration of KRAB activating proteins 
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and not in the activity of the domain (Chung et al., 2007). ZAD containing proteins may 
require the C-terminal zinc-finger double domains for proper co-factor binding (Jauch et 
al., 2003).  The activity of KRAB domain proteins is dependent upon the presence of a 
co-activator identified as the Kruppel Associate Protein-1 (KAP-1) (Friedman et al., 
1996).  KAP-1 is a member of the multi-component Transcriptional Intermediary Factor 1 
(TIF1) family, which in humans contains four structurally and functionally similar 
proteins (Khetchoumian et al., 2004; Le Douarin et al., 1995; Venturini et al., 1999).  
Although no direct binding factor of ZAD has currently been identified, there is a single 
TIF1 protein family member identified in D. melanogaster, Bonus (Bon) (Beckstead et 
al., 2001).  The presence of conserved activation and binding domains between the Homo 
sapiens PARIS and D. melanogaster CG15436 proteins provide a large base of evidence 
for homologous function across species.   
 PARIS is a directly binding inhibitor of the PGC-1α protein in Homo sapiens 
(Castillo-Quan, 2011); lowered expression would be predicted to result in a reduction of 
inhibition and thus an increase in mitochondrial biogenesis through elevated PGC-1α 
activity.  As the D. melanogaster eye provides an ideal tissue for the study of gene 
involvement in pathways of neurodevelopment as both ommatidia and bristle number can 
be easily quantified and allow for the distinction of subtle changes based on gene 
alteration, we expressed RNAi transgene constructs for our three putative PARIS 
homologues to determine the consequence they have on the formation of the eye tissues. 
 D. melanogaster eye specific expression of a Crol-RNAi transgene causes a severe 
disruption in the formation of ommatidia and bristles in the D. melanogaster eye.  The 
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CROL protein was most similar to PARIS (35% similarity) and has been implicated to 
play a role in leg morphogenesis.  Expression of Crol occurs in the imaginal discs of D. 
melanogaster eyes, suggesting that it may play a similar role in eye development 
(D'Avino & Thummel, 1998).  This is the first time altered Crol expression has been 
assessed and characterized in the D. melanogaster eye.  D. melanogaster eye specific 
expression of a CG15436-RNAi transgene resulted in no significant change in ommatidia 
or bristle number at 25°C or 29°C.  The CG15436 protein shares 33% similarity with the 
Homo sapiens PARIS protein and no role of the CG15436 protein has not yet been 
identified, however, it may act as a DNA binding transcription factor based on the 
presence of zinc finger motifs.  The third putative homologue, CG15269 shows a slight 
yet significant decrease in ommatidia number at 25°C and a severe decrease in both 
tissues at 29°C compared to UAS-lacZ controls.  This gene currently has no identified 
function but, like PARIS (which it shares 29% protein similarity with) and our other 
putative homologues, contains the zinc finger motifs associated with transcriptional 
repression.  We show the first evidence that CG15269 may play a role in the development 
of D. melanogaster eye tissue and that altered expression of this gene may lead to 
developmental defects in these tissues.  These eye specific developmental phenotypes 
associated with the loss of function of the three putative PARIS homologues CG15436, 
CG15269 and Crol have not been previously identified and could show involvement of 
all three genes in neuronal development.     
 With the Ddc-Gal4 transgene, the PARIS candidate genes were inhibited in the 
dopaminergic neurons to determine the consequence of improper gene function and 
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potential links to disease. Altered expression of CG15269 showed no effect on mean 
lifespan in DA neurons.  This result differs from the data obtained in the D. melanogaster 
eye, however, the eye is a more sensitive system allowing for the detection of subtler 
changes compared to aging assays.  Thus, it is possible that CG15269 does play a role in 
neuronal formation but does not have a strong enough effect when altered to cause 
premature organism mortality.  Expression of a Crol-RNAi construct caused a significant 
decrease in the mean longevity compared to control flies.  This supports the evidence 
found in the D. melanogaster eye that Crol is involved in neuronal tissues and altered 
expression of this gene leads to tissue disruption and in this case reduced mortality.  
Finally, altered expression of CG15436 caused a significant increase in mean lifespan 
compared to controls.  This result would be expected from the PARIS homologue as 
RNAi inhibition of that gene would cause an increase in mitochondrial biogenesis 
through the PGC-1α pathway.  Of the three putative PARIS homologues we identified and 
characterized, CG15436 is the best candidate and may be the D. melanogaster homologue 
of PARIS.   
 In this study, we identified and evaluated potential D. melanogaster functional 
homologues of the recently discovered human gene PARIS.  Finding a functional 
homologue of PARIS would provide a better D. melanogaster model of the srl-mediated 
pathway of mitochondrial biogenesis initiated by the PD gene Parkin.  Through this 
process, we have found that three uncharacterized genes having a neuronal function: Crol, 
CG15436 and CG15269 are important in the proper function of both dopaminergic and 
precursor eye tissue neurons.  Of these three genes, we found that CG15436 is the most 
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PARIS-like in both structure and function.  Fully characterizing the D. melanogaster 
pathway of mitochondrial biogenesis will allow for a more precise model to study human 
disease and potential preventative treatments for neurodegenerative disease.   
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Chapter 6 - Summary 
6.1. Summary 
 The work presented in this thesis expands the current working knowledge of 
Parkinson Disease model biology in D. melanogaster.  In recent years there has been a 
shift from the existing belief that PD onset is solely sporadic in origin.  Advances in the 
fields of molecular biology and genetics have allowed for specific identification of 
mutations leading to PD via single patient genome comparison and large scale screening.  
How gene dysfunction and mutation contribute to the onset and clinical symptoms of PD 
is a complex and difficult to answer question.  Although monogenic forms of inherited 
PD do make up approximately 30% of cases (Klein & Westenberger, 2012), most variants 
involve multiple environmental, epigenetic and genetic factors that eventually result in a 
parkinsonian phenotype (Labbe & Ross, 2014).  Many characterized gene mutations 
leading to disease phenotypes inhibit the proper function of the intracellular proteasome 
complex or organelle function (Lim, 2007; Ryan et al., 2015).  I have looked at two 
separate yet equally important pathways that have been linked to the onset of PD when 
protein activity is altered.  The first involves the processes governing proper 
mitochondrial upkeep and repair.  The second involves ubiquitin ligase attachment and 
the subsequent proteasomal activity leading to proper destruction and recycling of 
unwanted and potentially dangerous cellular components.  Determining why these 
complex processes breakdown and what genes are essential and imperative to proper 
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pathway function may lead to new therapeutic targets and future research goals aimed at 
not just alleviating symptoms but preventing PD altogether. 
 Chapter 2 of this thesis investigated the D. melanogaster homologue of the human 
PD causing gene PGC-1α.  PGC-1α functions as a growth factor and is one of three genes 
in the PGC family responsible for the activation of signals leading to mitochondrial 
biogenesis (Jornayvaz & Shulman, 2010).  PGC-1α itself is up-regulated under conditions 
of stress and fasting while the other members of this gene family are constituently 
expressed in tissues at a basal level, making it difficult to determine the effect of altered 
PGC-1α expression in mammalian models (Gleyzer & Scarpulla, 2011; Meirhaeghe et 
al., 2003; Mortensen et al., 2007).  I investigated the sole D. melanogaster homologue of 
PGC-1α, spargel, to determine the effect of altered PGC pathway expression on the 
development of neurons.  SRL was previously characterized as a growth factor and whole 
flies containing a hypomorph of this gene have stunted growth and small body size 
compared to wild type control flies (Tiefenbock et al., 2010).  After performing a 
bioinformatics analysis of the SRL protein and comparing the functional domains present 
with all three members of the PGC family, I believed that srl was the D. melanogaster 
homologue of PGC-1α.  To determine if aberrant srl function could cause the 
neurodegeneration found in the brains of H. sapiens patients with abnormal PGC-1α 
activity, I expressed srl-RNAi and srl-EY transgene constructs in the D. melanogaster 
eye.  As expected, decreasing srl expression caused a degenerative phenotype while 
increasing srl seemed to have no real effect on the development of the eye through 
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neuronal precursors with the exception of a slight decrease in ommatidia and bristles at 
29°C.   
 Next, I expressed the srl-RNAi and srl-EY transgene constructs in dopaminergic 
neurons to attempt and mimic the neurodegeneration found in PD patients and produce a 
new model of disease.  Dopaminergic expression of srl-RNAi resulted in a significant 
increase in lifespan while srl-EY expression decreased mean longevity compared to lacZ 
controls.  This result was unexpected but remained consistent when the assay was 
repeated at 29°C.  Altered srl expression leads to different phenotypes depending on the 
tissue in question.  Overexpression of srl in tissues with high energy requirements, such 
as intestinal cells, digestive cells and cardiac muscle leads to an increased lifespan, while 
overexpression of srl in the whole organism decreases mean lifespan (Rera et al., 2011; 
Tinkerhess et al., 2012).  Thus, is it not surprising that directed srl expression in the eye 
did not lead to the same phenotype as directed srl expression in a tissue with a much 
higher energy requirement such as dopaminergic neurons.  Locomotor assays performed 
on the same genotypes showed that flies do not perform better in climbing tests despite 
living longer, suggesting that although flies are living longer they may still be 
experiencing neuronal dysfunction.   
Two significant results were produced as a result of this research project.  The 
first is the characterization of a new model of PD in D. melanogaster, obtained through 
the tissue specific expression of srl-EY in dopaminergic neurons.  Expression of this 
construct results in a phenotype with decreased mean longevity and decreased locomotor 
ability compared to a control.  The second is the result found through the dopaminergic 
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expression of a srl-RNAi construct.  Expression of this construct increases the mean 
longevity of flies compared to controls, but does not increase the locomotor ability, 
leading to flies that outlive control counterparts but are unable to perform basic locomotor 
movements throughout that increase in lifespan.  There are two potential explanations for 
this result, both involving inducible stress pathways that result in increased organism 
longevity.  The first potential explanation involves the induction of the unfolded protein 
response pathway, while the second involves the formation of low level reactive oxygen 
species, which in turn provoke cellular anti-oxidants, causing a stronger response to 
future stress exposure and is known as mitohormesis (Haynes & Ron, 2010; Ristow & 
Schmeisser, 2014).  It is my suggestion that future work on this project should aim to 
determine what pathways are upregulated when srl-RNAi is expressed in dopaminergic 
neurons via by searching for interactors in a modifier of phenotype screen.  This 
experiment should focus on known stress response genes, specifically those involved in 
the unfolded protein response and reactive oxygen mitigation.  Identification of a pathway 
stimulated by srl-RNAi expression in dopaminergic neurons could lead to new therapeutic 
targets for eventual disease prevention. 
 For Chapter 3 of this thesis, I investigated the potential homologue of the gene 
responsible for a severe early onset form of PD, FBXO7.  FBXO7 functions as the 
targeting component of the SCF ubiquitin ligase complex and point mutations in this gene 
have been directly linked to parkinsonian pyramidal syndrome (Di Fonzo et al., 2009; 
Gunduz et al., 2014).  A putative homologue of FBXO7, ntc, has been identified in D. 
melanogaster but only characterized as a mediator of terminal sperm differentiation 
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(Bader et al., 2010).  A second gene of interest, PI31, functions as a stabilizing 
component of the SCF ubiquitin complex and must bind directly to FBXO7 for proper 
complex function (Kirk et al., 2008).  PI31 has also been characterized as an inhibitor of 
proteasome activity when it is not bound and freely available within the cell (Li et al., 
2014).  This project aimed to confirm ntc was the D. melanogaster homologue of FBXO7 
through bioinformatics analysis, followed by determining if aberrant function of ntc in 
neuronal tissues could lead to the degenerative phenotypes associated with the Homo 
sapiens FBXO7 gene.  Additionally, we aimed to evaluate the D. melanogaster 
homologue of PI31 and determine if it was necessary for proper proteasome activity in 
neuronal tissues, mimicking the complex found in Homo sapiens.   
 I compared the protein sequences and domains of FBXO7 and PI31 from H. 
sapiens with the putative D. melanogaster homologues and found a high degree of 
similarity.  Both FBXO7 and NTC contain a PI31 binding domain and an F-Box domain, 
indicating that they may provide a similar function in both organisms.  To confirm this, I 
also compared the protein sequence and domains of PI31 between H. sapiens and D. 
melanogaster and found a strong similarity, the sequences differing in length by only a 
single amino acid and containing the same proteasome binding and FBXO domains.  
Since it appeared the D. melanogaster homologues ntc and PI31 were structurally similar 
to their Homo sapiens counterparts, I next wanted to determine if altered expression of 
these genes could lead to neurodegenerative phenotypes.  I began by directing expression 
of four transgene constructs in the D. melanogaster eye: ntc-RNAi, ntc-EY, PI31-RNAi 
and PI31-EY.  Altered expression of both ntc and PI31 was sufficient to cause a 
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degenerative phenotype.  This phenotype was most severe with PI31.  This result was 
replicated when the transgene constructs were expressed directly in dopaminergic 
neurons, suggesting that ntc and PI31 are tightly regulated in both the eye and 
dopaminergic neurons of D. melanogaster.  However, in dopaminergic neurons, ntc did 
show a more severe decrease in longevity compared to controls than PI31, suggesting 
perhaps a greater role for this gene specifically in tissues with high energetic 
requirements due to the increased response found in the dopaminergic neurons versus the 
D. melanogaster eye. 
 The classical D. melanogaster model of PD involves the ectopic expression of H. 
sapiens α-synuclein to induce a PD like phenotype of locomotor disruption and 
destruction in dopaminergic neurons (Feany & Bender, 2000).  This phenotype mimics 
the H. sapiens model of PD in which harmful α-synuclein aggregates are created in 
dopaminergic neurons eventually leading to cell death (Baba et al., 1998).  This 
phenotype has been shown with pan neuronal expression by use of an elav-Gal4 driver 
but I was unable to replicate the longevity reducing phenotype in our flies.  This putative 
model involves the accumulation of harmful proteinaceous inclusions that lead to cell 
death when cellular machinery is no longer able to negate their formation (Navarro et al., 
2014).  One such method of removing harmful components is the ubiquitin mediated 
proteasome complex.  Since PI31 and NTC are components of a ubiquitin ligase complex 
responsible for the targeting of the proteasome, I assayed the potential cumulative effect 
of mutation in ntc and PI31 along with ectopic expression of α-synuclein in the 
dopaminergic neurons of D. melanogaster.  Co-expression of α-synuclein and PI31-RNAi 
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resulted in a decrease in mean longevity, indicating that altered PI31 expression coupled 
with an abundance of aberrant protein inclusions significantly decreases lifespan 
compared to controls.  Alternatively, co-expression of α-synuclein and PI31-EY did not 
significant impact longevity indicating that the decrease in longevity found when PI31-
EY was expressed by itself may be abrogated by the presence of harmful protein clusters, 
this is an unexpected result and requires further work to confirm.  Interestingly, the co-
expression of α-synuclein and ntc-RNAi resulted in a significant increase in lifespan 
compared to α-synuclein and lacZ expressing controls.  However, as I found with the 
expression of srl-RNAi in dopaminergic neurons, these flies do not differ significantly 
from the control group in locomotor activity, indicating a decrease in mobility over time.   
 This experiment resulted in the identification and classification of two new D. 
melanogaster models of PD in which longevity is reduced and neuronal tissues are 
disrupted by altered expression of these genes.  Altered expression of both ntc and PI31 
in the eye and dopaminergic neurons of D. melanogaster caused tissue destruction and 
decreased longevity indicative of the neuronal dysfunction and destruction found in forms 
of PD.  This indicates not only that ntc and PI31 are likely the D. melanogaster 
homologues of Homo sapiens FBXO7 and PI31 but also that the stabilizing activity of 
PI31 is conserved between species.  Future experiments should focus on creating a double 
mutant construct of both ntc and PI31 and assaying the degenerative effect on the D. 
melanogaster eye.  It may also be pertinent to determine which of these genes is the rate 
limiting factor in the activity of this ubiquitin proteasome complex which may be done by 
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attempting a rescue of the degenerative phenotype caused by a decrease in one gene by 
overexpression of the other.     
I found evidence that expression of ntc-RNAi in dopaminergic neurons also expressing α-
synuclein increases the mean longevity compared to α-synuclein and lacZ expressing 
controls.  This is an interesting result and it is my suggestion that follow up experiments 
focus on the cause of this increase and what additional survival mechanisms may be 
invoked within the organism.  A simple starting point for this analysis would be to assess 
the level of gene expression between experimental and control flies in a micro-array and 
compare the genes with higher or lower expression to those implicated in stress response 
mechanisms. 
 F-box genes perform essential cellular functions, targeting specific intracellular 
components for destruction via ubiquitination.  Given this information, it is not surprising 
that a sub-family of FBXO genes, including FBXO7 and FBXO32, shows degenerative 
phenotypes in neurons and muscle tissue, respectively, when altered through mutation 
(Bodine & Baehr, 2014; Di Fonzo et al., 2009).  The third member of this gene sub-
family, FBXO9, has not been well characterized in H. sapiens, though it was implicated 
as a possible growth factor involved in multiple myeloma (Fernandez-Saiz et al., 2013).  I 
looked at the putative D. melanogaster homologue of this gene, CG5961, to determine if 
altered expression in neuronal tissues could cause a degenerative phenotype found 
associated with other gene sub-family members.   
 A comparison of the FBXO9 and CG5961 proteins shows full conservation of all 
domains present and almost an identical length in terms of amino acid sequence.  An 
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alignment of these proteins shows the most similarity in the F-box binding domain, 
indicating that the original function of FBXO9 is likely conserved across species.  Altered 
expression of CG5961 in the D. melanogaster eye caused a significant disruption of 
neuronal tissue formation.  This effect was found for expression of both a CG5961-RNAi 
and CG5961-EP construct, but it was interesting to note that increased expression of 
either of these constructs via higher temperature growth did not seem to amplify the 
negative effect, suggesting that CG5961 may not be sufficient to fully disrupt tissue 
formation alone.  Having established a neuronal role of CG5961 in the eye, I next 
expressed the CG5961 constructs directly in the dopaminergic neurons of flies.  Both 
constructs significantly lowered the mean longevity of flies compared to lacZ controls.   
 The main result of Chapter 4 is that altered expression of CG5961 causes 
neurodegenerative phenotypes in both the eye and dopaminergic neurons of D. 
melanogaster.  CG5961 was previously uncharacterized and I present the first evidence of 
a function for this gene in neuronal tissues.  It appears as though it is tightly regulated 
specifically in the dopaminergic neurons, as altered expression in either direction results 
in a significant loss in mean longevity, similar to the results found with ntc.  Future work 
on this project should integrate CG5961 into the larger project focused upon ntc, and 
PI31.  The initial theory that all three members of this sub-family of FBXO genes have 
ties to degeneration appears to be correct and studies of the Homo sapiens FBXO9 gene 
should also look into potential links between that gene and human disease.  
 The process of mitochondrial biogenesis is mediated through the PGC family of 
proteins, while the parallel process of mitochondrial upkeep and turnover is mediated 
  
133 
 
through the Pink1 / Parkin pathway (Eiyama & Okamoto, 2015; Jornayvaz & Shulman, 
2010).  Between these pathways is a regulatory protein known as PARIS.  PARIS is a 
transcriptional repressor of PGC-1α that is susceptible to destruction by the ubiquitin 
ligase activity of Parkin (Shin et al., 2011).  Since PARIS is the direct link between the 
processes of mitochondrial upkeep / turnover and biogenesis, I wanted to query the 
genome of D. melanogaster for a potential PARIS gene homologue.  A BLAST search 
using Homo sapiens PARIS as a query resulted in three potential matches in the D. 
melanogaster genome: CROL, CG15436 and CG15269.  A detailed analysis of PARIS 
revealed a KRAB zinc finger domain and a zinc double finger domain.  Each of the 
candidate D. melanogaster proteins contained the zinc double finger domain, but only 
CG15436 contained a domain homologous to the KRAB domain of PARIS.  A direct 
comparison of the amino acid sequence of the KRAB domain with the homologous ZAD 
domain revealed a high degree of similarity, suggesting CG15436 was the most likely 
homologue of the three candidates.   
 To determine if any of the three candidate genes were involved in pathways of 
neuronal development, I directed expression of transgene constructs expressing an RNAi 
for each gene in the D. melanogaster eye.  Surprisingly, altered expression of both Crol 
and CG15269 resulted in a degenerative phenotype compared to lacZ controls while 
CG15436 did not significantly change the development of the tissues of the eye.   A 
comparison of the eye phenotype generated from expression of CG15436-RNAi with the 
phenotypes generated by the altered expression of srl showed that the srl-EY construct 
was most similar in terms of effect on ommatidia and bristles.  After finding that both 
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Crol and CG15269 had negative consequences on neuronal development, I directed 
expression of all three constructs in dopaminergic neurons.  Expression of Crol-RNAi 
caused a significant decrease in lifespan while CG15436-RNAi caused a significant 
increase.   
 This line of experiments resulted in three significant findings.  The first is the 
unexpected neuronal destruction caused by the altered expression of Crol in both the eye 
and dopaminergic neurons of D. melanogaster.  This is the first experiment we are aware 
of, suggesting a neuronal function for Crol which is characterized as a negative regulatory 
factor in limb development (D'Avino & Thummel, 1998).  The second is the neuronal 
destruction imparted by the altered expression of CG15269, a gene previously not 
characterized and with no known function.  Both Crol and CG15269 should be further 
evaluated in neuronal cells. It is my suggestion that constructs overexpressing these genes 
are used in a follow up study to further identify their role in neuronal development in both 
the eye and dopaminergic neurons.  Furthermore, the role of these proteins may be 
determined through modifier screening.  The third is the similar phenotype produced by 
the directed eye expression of both CG15436-RNAi and srl-EY.  Coupled with the 
increase in life witnessed with the dopaminergic expression of CG15436-RNAi, it would 
appear that CG15436 is the best preliminary candidate for a D. melanogaster homologue 
of PARIS.  Additional experiments are necessary to confirm that CG15436 is the D. 
melanogaster homologue of PARIS.  CG15436 appears to be able to extend lifespan when 
removed in the dopaminergic neurons of D. melanogaster indicating that it may be a 
repressor of a necessary neuronal factor such as srl.  Experiments in Homo sapiens have 
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found that Parkin loss leads to declines in mitochondria number and size, indicative of a 
loss in mitochondrial biogenesis due to the increased inhibition of PGC-1α that results 
from an overabundance of PARIS (Stevens et al., 2015).  If a D. melanogaster line 
combining the expression of Parkin-RNAi and CG15436-RNAi shows a rescue phenotype 
versus a line expressing only Parkin-RNAi, it would confirm the identity of CG15436 as 
the PARIS homologue.  Alternatively, a western blot could be performed on Parkin 
mutant flies versus wild type flies to compare the amount of CG15436 protein.  A 
decrease in CG15436 in a Parkin mutant would infer that the E3 ubiquitin ligase activity 
of PARKIN is responsible for the destruction of this gene as is found in the H. sapiens 
system with Parkin and PARIS. 
6.2. Limitations in Interpretation 
 There are a number of limitations in interpretation that is present in this work due 
both to technical reasons and flaws in experimental design.  To determine the effect of 
putative homologues of H. sapiens neurodegenerative causative genes, we decreased 
expression through RNAi and increased expression by means of the Gal4-UAS transgene 
system with the targeting eye driver GMR-Gal4.  This provides a visual model of 
destruction that has been traditionally correlated with degeneration, however, we have not 
actually quantified or tested these tissues for a degenerative effect.  No molecular analysis 
of the components of these eye tissues was undertaken.  This limitation could be 
overcome by assaying for proteins related to apoptotic or autophagic processes within the 
cells of these eyes.   
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 The transgenes employed have been previously characterized by other groups, 
however, I did not assay the expression of these transgenes personally.  It is possible that 
the assays completed by other groups were not correct and that these transgenes were 
guilty of providing off target effects or alternative expression then indicated by the 
genotype.  This could be rectified by performing a western blot of the proteins targeted by 
these transgenes to confirm expression of the resulting protein is either lowered or 
increased in tissues of interest.  Without this analysis it is not possible to say with 
certainty that no confounding effects were introduced into our study.  I did utilize more 
than a single RNAi for both the srl and ntc RNAi expression analysis which helps 
alleviate this effect in these datasets.  In a number of instances data revealed that both the 
RNAi and UAS transgenes had a similar effect on development of the D. melanogaster 
eye.  I have attempted to explain this effect by inferring that the gene in question is 
necessary in a specific amount for neurons to develop appropriately.  It is possible that the 
expression of any non-native protein in these tissues causes a negative developmental 
response and that the added stress of raising flies at 29°C increases this response.  
Molecular work to assay the amount of protein expression in these cases would help to 
explain some of the effects witnessed in these assays.  If a gene is highly regulated and 
altered expression in any direction causes a severe degenerative phenotype additional 
experiments aiming to exacerbate this phenotype could be undertaken (expression of two 
UAS constructs together or additional RNAi). 
 To determine the effect of dopaminergic expression of the potential gene 
homologues we expressed RNAi and UAS lines of these homologues in the dopaminergic 
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neurons by use of a dopamine decarboxylase (Ddc)-Gal4 driver.  I choose this driver 
because there is currently a discussion in the literature with regards to the efficacy of 
tyrosine hydroxylase (Th)-Gal4 as a driver for reproducible dopaminergic expression and 
also because this driver in my hands was not consistent in result (Whitworth, 2011).  Ddc 
is expressed in dopaminergic and serotonergic neurons and as a result it is possible that 
the results obtained are not entirely due to dopaminergic neuron expression of the 
potential gene homologues.  Serotonergic neurons have recently been implicated to play a 
role in H. sapiens forms of PD and, as such, expression of our putative homologue genes 
in these tissues could be giving our results a stronger effect then would be found in 
dopaminergic neurons alone (Zhang et al., 2008).  Further confounding our analysis of 
altered gene expression in dopaminergic neurons is the knowledge that dopamine is also 
expressed in the cuticle and involved in melanin production (Yamamoto & Seto, 2014).  
It has been shown that a full knockout of dopaminergic neurons leads to larval lethality 
(Riemensperger et al., 2011).  This dopaminergic neuron production of melanin is not 
conserved in higher animals such as H. sapiens, making the D. melanogaster model of 
dopamine related neurodegeneration more complex.   Contrary to this point D. 
melanogaster are simple organisms compared to H. sapiens and lack the high complexity 
required to fully develop models of neurodegenerative disease.  This has been discussed 
in Chapter 1 as a strength and weakness of this model.  Finally, given the information 
obtained for gene homologues through comparison of protein domains and an NCBI 
BLAST comparing proteins to the D. melanogaster whole genome it is not possible for 
me to make a true homology call between PARIS, FBXO7, or FBXO9 and a fly 
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homologue.  Additional assays need to be undertaken to confirm that any of these three 
genes are the direct D. melanogaster homologue of the H. sapien disease causative gene.  
A simple rescue assay introducing the H. sapiens protein in tandem with a knock down of 
the D. melanogaster protein could be an efficient step in proving this homology.   
6.3. Conclusion 
 The work I have documented in this thesis provides a number of new models of 
Parkinson Disease in Drosophila melanogaster that may be expanded upon and studied to 
further current knowledge of disease onset and progression in Homo sapiens.  Originally, 
it was known that the Homo sapiens genes PGC-1α, FBXO7, PI31 and PARIS were 
implicated as causative factors in Parkinson Disease etiology.  I have provided evidence 
that each of these genes have functional homologues in D. melanogaster and that altered 
expression of these homologues leads to neurodegenerative phenotypes in two separate 
neuronal tissues: the eye and dopaminergic neurons.  Additionally, I have shown that 
Crol, CG15269 and CG5961, genes previously not linked to neuronal development, cause 
a degenerative phenotype when expression is altered in neuronal tissues. 
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Appendix 1 – Supplemental Material for Chapter 2 
S1.1.  Statistical breakdown and comparison of ommatidia and bristle number counts between 
lacZ control and srl transgene constructs in the Drosophila melanogaster eye 
 
A. Ommatidia Number 25°C, control mean 751.20 ommatidia per eye 
Genotype Number of 
eyes (N) 
Mean difference in 
number vs control 
p-value 
compared to 
control 
Standard 
Deviation 
GMR-Gal4;UAS-lacZ 10 N/A N/A 27.5431 
GMR-Gal4;UAS-srlRNAi1 10 25.00 <0.05 15.23009 
GMR-Gal4;UAS-srlRNAi2 10 4.80 >0.05 16.61459 
GMR-Gal4;UAS-srl 10 16.80 >0.05 16.34489 
 
B. Ommatidia Number 29°C, control mean 644.90 ommatidia per eye 
Genotype Number of 
eyes (N) 
Mean difference in 
number vs control 
p-value 
compared to 
control 
Standard  
Deviation 
GMR-Gal4;UAS-lacZ 10 N/A N/A 26.69353 
GMR-Gal4;UAS-srlRNAi1 10 94.70 <0.0001 59.60015 
GMR-Gal4;UAS-srlRNAi2 10 70.10 <0.0001 34.66603 
GMR-Gal4;UAS-srl 10 -41.30 >0.05 28.81666 
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C. Bristle Number 25°C, control mean 617.30 bristles per eye 
Genotype Number of 
eyes (N) 
Mean difference in 
number vs control 
p-value 
compared to 
control 
Standard  
Deviation 
GMR-Gal4;UAS-lacZ 10 N/A N/A 21.55639 
GMR-Gal4;UAS-srlRNAi1 10 63.70 <0.0001 6.834553 
GMR-Gal4;UAS-srlRNAi2 10 64.20 <0.0001 18.00278 
GMR-Gal4;UAS-srl 10 55.30 <0.0001 9.614803 
 
D. Bristle Number 29°C, control mean 507.10 bristles per eye 
Genotype Number of 
eyes (N) 
Mean difference in 
number vs control 
p-value 
compared to 
control 
Standard  
Deviation 
GMR-Gal4;UAS-lacZ 10 N/A N/A 16.79583 
GMR-Gal4;UAS-srlRNAi1 10 118.40 <0.0001 43.40264 
GMR-Gal4;UAS-srlRNAi2 10 63.20 <0.0001 10.89801 
GMR-Gal4;UAS-srl 10 -15.60 >0.05 26.20454 
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Table S1.2.  Log-rank (mantel cox) survival analysis comparison of altered srl transgene 
constructs and lacZ control 
A. Longevity at 25°C 
Genotype Number 
of Flies 
(N) 
Median 
Survival 
(Days) 
p-value 
compared to 
control 
Significant 
Ddc-Gal4;UAS-lacZ 324 76 N/A N/A 
Ddc-Gal4;UAS-srlRNAi 400 90 <0.0001 Yes 
Ddc-Gal4;UAS-srl 373 64 <0.0001 Yes 
 
B. Longevity at 29°C 
Genotype Number 
of Flies 
(N) 
Median 
Survival 
(Days) 
p-value 
compared to 
control 
Significant 
Ddc-Gal4;UAS-lacZ 158 38 N/A N/A 
Ddc-Gal4;UAS-srlRNAi 151 42 <0.0001 Yes 
Ddc-Gal4;UAS-srl 214 34 <0.0001 Yes 
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Table S1.3.  Statistical comparison of climbing index curves between lacZ control and srl 
transgene constructs 
 
Genotype Rate (k) Standard 
error 
95% 
Confidence 
interval 
R2 P value 
Ddc-Gal4;UAS-lacZ 0.05600 0.002425 0.05114 to 
0.06087 
0.9572 N/A 
Ddc-Gal4;UAS-
srlRNAi 
0.04856 0.002107 0.04434 to 
0.05278 
0.9561 0.7598 
Ddc-Gal4;UAS-srl 0.05897 0.005450 0.04795 to 
0.06998 
0.8333 0.6163 
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Appendix 2 – Supplemental Material for Chapter 3 
S2.1. Protein sequence alignment of Homo sapiens FBXO7 and Drosophila melanogaster NTC.  
Alignment performed in ClustalW2.  Purple = F-Box domain.   
 
 
  
ntc             --MSDTKSEIEGFIAIPTTSGEQQQQQPQQQQ-------------------NEQQVVGTK 39 
FBXO7           MRLRVRLLKRTWPLEVPETEPTLGHLRSHLRQSLLCTWGYSSNTRFTITLNYKDPLTGDE 60 
                  :     :    : :* *.    : :.: :*                    :: :.* : 
 
ntc             DIKAPDQVGKKQRPRLIQEKSTQETNPLILEHATLEWVPQHMDKLLNQYQECRKMPAAEW 99 
FBXO7           ETLASYGIVSGDLICLILQDDIPAPNIPSSTDSEHSSLQNNEQPSLATSSNQTSMQDEQP 120 
                :  *.  : . :   ** :..   .*     .:  . : :: :  *   .:  .*   :  
 
ntc             LHLLTYLVALECGFVEEETFAQKRHLIQPVPSFSSFHAQNVRILSEQPARYEVCFN---- 155 
FBXO7           SDSFQGQAAQSGVWNDDSMLGPSQNFEAESIQDNAHMAEGTGFYPSEPMLCSESVEGQVP 180 
                 . :   .* .  : ::. :. .:::     . .:. *:.. : ..:*   . ..:     
 
ntc             -----------------DTVYIMRLRTLLDKHAPEETS---------------------- 176 
FBXO7           HSLETLYQSADCSDANDALIVLIHLLMLESGYIPQGTEAKALSMPEKWKLSGVYKLQYMH 240 
                                   : :::*  * . : *: *.                       
 
ntc             -LVAALQCRLMAVSLGDQLMITLSPAPPSKEPGYSVSLSIGRYVLNIQAKNKPIYHRFRK 235 
FBXO7           PLCEGSSATLTCVPLGNLIVVNATLKINNEIRSVKRLQLLPESFICKEKLGENVANIYKD 300 
                 *  . .. * .*.**: :::. :    .:  . .    : . .:  :  .: : : ::. 
 
ntc             LDELSYQLKQHLFQPMRSQQLMQMEMKLQPSLLGLPDELYFEIFRYLDKSQLNVVARVNR 295 
FBXO7           LQKLSRLFKDQLVYPLLAFTRQALNLPDVFGLVVLPLELKLRIFRLLDVRSVLSLSAVCR 360 
                *::**  :*::*. *: :     :::    .*: ** ** :.*** **  .:  :: * * 
 
ntc             HLHFYS--------------------------------KEVERKRLKGGRS--------- 314 
FBXO7           DLFTASNDPLLWRFLYLRDFRDNTVRVQDTDWKELYRKRHIQRKESPKGRFVMLLPSSTH 420 
                .*.  *                                :.::**.   **           
 
ntc             ------------------------------------------------------------ 
FBXO7           TIPFYPNPLHPRPFPSSRLPPGIIGGEYDQRPTLPYVGDPISSLIPGPGETPSQFPPLRP 480 
                                                                             
 
ntc             ------------------------------------------ 
FBXO7           RFDPVGPLPGPNPILPGRGGPNDRFPFRPSRGRPTDGRLSFM 522 
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S2.2. Statistical breakdown and comparison of ommatidia and bristle number counts between 
lacZ control, ntc, and PI31 transgene constructs in the Drosophila melanogaster eye 
A. Ommatidia Number 25°C, control mean 752.4 ommatidia per eye 
Genotype Number of 
eyes (N) 
Mean difference in 
number vs control 
p-value 
compared to 
control 
Standard 
Deviation 
GMR-Gal4;UAS-lacZ 10 N/A N/A 25.012 
GMR-Gal4;UAS-ntcRNAi 10 64.60 <0.0001 25.012 
GMR-Gal4;UAS-ntc 10 63.20 <0.0001 16.91679 
GMR-Gal4;UAS-PI31RNAi 10 24.90 >0.05 26.86696 
GMR-Gal4;UAS-PI31 10 20.90 >0.05 26.85765 
 
B. Ommatidia Number 29°C, control mean 714.40 ommatidia per eye 
Genotype Number of 
eyes (N) 
Mean difference in 
number vs control 
p-value 
compared to 
control 
Standard  
Deviation 
GMR-Gal4;UAS-lacZ 10 N/A N/A 25.85085 
GMR-Gal4;UAS-ntcRNAi 10 328.70 <0.0001 34.75054 
GMR-Gal4;UAS-ntc 10 26.70 >0.05 9.381424 
GMR-Gal4;UAS-PI31RNAi 10 190.90 <0.0001 31.08858 
GMR-Gal4;UAS-PI31 10 149.90 <0.0001 21.32708 
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C. Bristle Number 25°C, control mean 596.90 bristles per eye 
Genotype Number of 
eyes (N) 
Mean difference in 
number vs control 
p-value 
compared to 
control 
Standard 
Deviation 
GMR-Gal4;UAS-lacZ 10 N/A N/A 15.97533 
GMR-Gal4;UAS-ntcRNAi 10 95.80 <0.001 7.81807 
GMR-Gal4;UAS-ntc 10 97.30 <0.0001 71.79013 
GMR-Gal4;UAS-PI31RNAi 10 78.90 <0.0001 49.0374 
GMR-Gal4;UAS-PI31 10 75.90 <0.0001 23.04585 
 
D. Bristle Number 29°C, control mean 498.20 bristles per eye 
Genotype Number of 
eyes (N) 
Mean difference in 
number vs control 
p-value 
compared to 
control 
Standard  
Deviation 
GMR-Gal4;UAS-lacZ 10 N/A N/A 22.77816 
GMR-Gal4;UAS-ntcRNAi 10 112.50 <0.0001 40.61144 
GMR-Gal4;UAS-ntc 10 53.60 >0.05 50.2664 
GMR-Gal4;UAS-PI31RNAi 10 229.9 <0.0001 28.42944 
GMR-Gal4;UAS-PI31 10 193.7 <0.0001 36.47221 
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S2.3. Log-rank (mantel cox) survival analysis comparison of altered ntc, PI31, and FBXO9 
transgene constructs with lacZ control 
A. Longevity of ntc and PI31 trial 1 of 2 
Genotype Number 
of Flies 
(N) 
Median 
Survival 
(Days) 
p-value 
compared to 
control 
Significant 
Ddc-Gal4;UAS-lacZ 292 54 N/A N/A 
Ddc-Gal4;UAS-ntcRNAi 317 38 <0.0001 Yes 
Ddc-Gal4;UAS-PI31RNAi 314 46 <0.0001 Yes 
Ddc-Gal4;UAS-PI31 361 46 <0.0001 Yes 
 
B. Longevity of ntc and PI31 trial 2 of 2 
Genotype Number 
of Flies 
(N) 
Median 
Survival 
(Days) 
p-value 
compared to 
control 
Significant 
Ddc-Gal4;UAS-lacZ 215 58 N/A N/A 
Ddc-Gal4;UAS-ntcRNAi 208 42 <0.0001 Yes 
Ddc-Gal4;UAS-ntc 214 38 <0.0001 Yes 
Ddc-Gal4;UAS-PI31RNAi 202 51 <0.0001 Yes 
Ddc-Gal4;UAS-PI31 199 52 <0.0001 Yes 
 
  
  
150 
 
S2.4.  Log-rank (mantel cox) survival analysis comparison of altered ntc and PI31 transgene 
constructs in an α-synuclein background using UAS-lacZ as a control 
Genotype Number of 
Flies (N) 
Median 
Survival 
(Days) 
p-value compared 
to control 
Significant 
Ddc-Gal4/UAS-α-syn;UAS-lacZ 295 56 N/A N/A 
Ddc-Gal4/UAS-α-syn;UAS-ntcRNAi 275 68 <0.0001 Yes 
Ddc-Gal4/UAS-α-syn;UAS-PI31RNAi 296 40 <0.001 Yes 
Ddc-Gal4/UAS-αsyn;UAS-PI31 252 54 >0.05 No 
 
S2.5.  Statistical comparison of climbing index curves between LacZ control, ntc and PI31 
transgene constructs 
Genotype Rate (k) Standard error 95% Confidence 
interval 
R2 Significant 
Ddc-Gal4/UAS-α-syn;UAS-
lacZ 
0.1026 0.005079 0.09243 to 0.1129 0.9658 N/A 
Ddc-Gal4/UAS-α-syn;UAS-
ntcRNAi 
0.06986 0.004319 0.06117 to 0.07855 0.9314 No 
Ddc-Gal4/UAS-α-syn;UAS-
PI31RNAi 
0.6317 0.6638 N/A 0.8176 No 
Ddc-Gal4/UAS-αsyn;UAS-PI31 0.2968 0.05522 0.1847 to 0.4089 0.6505 No 
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Appendix 3 – Supplemental Material for Chapter 4 
S3.1. Alignment and annotation of Homo sapiens FBXO9 and the Drosophila melanogaster 
putative FBXO9 homologue.  Alignment done with ClustalW2.  Bold = microtubule interacting 
and transporting domain, Yellow = Tetratricopeptide repeat, Purple = F-box domain, Underline = 
HNHc domain, Green = nuclear localization sequence. 
 
 
  
FBXO9h          MAEAEEDCHSDTVRADDDEENESPAETDLQAQLQMFRAQWMFELAPGVSSSNLENRPCRA 60 
CG5961          -------------MSDVDSDGEEPTRKTGTNALDEFRENWQRELQEHTTNTGSRSHSEAG 47 
                              :* *.:.*.*:..     *: ** :*  **   .:.:. ..:.  . 
 
FBXO9h          ARGSLQKTSADTKGKQEQAKEEKARELFLKAVEEEQNGALYEAIKFYRRAMQLVPDIEFK 120 
CG5961          DR----LTAANSNLSEADLLQAKAESLYRTAVQLEQRGKVYDALPFYRKATQIVPDIEFR 103 
                 *     *:*::: .: :  : **..*: .**: **.* :*:*: ***:* *:******: 
 
FBXO9h          ITYTRSP-------------DGDGVGNSYIEDNDDDSKMADLLSYFQQQLTFQ-----ES 162 
CG5961          FYEQQKQKLSNDVSKKYLNLANDLAKQLDLGQSDGEEVVDNLYEKFQHDLRQKNIYNGKM 163 
                :   :.               .* . :  : :.*.:. : :* . **::*  :     :  
 
FBXO9h          VLKLCQPELESSQIHISVLPMEVLMYIFRWVVSSDLDLRSLEQLSLVCRGFYICARDPEI 222 
CG5961          IASSRDANVLTTGLHFADLPPEIVMRILRWVVSAQLDMRSLEQCAAVCKGFYVYARDEEL 223 
                : .  :.:: :: :*:: ** *::* *:*****::**:***** : **:***: *** *: 
 
FBXO92          WRLACLKVWGRSCIKLVP--------YTSWREMFLERPRVRFDGVYISKTTYIRQGEQSL 274 
CG5961          WRLACVKVWGHNVGTLEAQDSDVSNVFHSWRDMFIRRDRVLFNGCYISKTTYLRMGENSF 283 
                *****:****:.  .* .        : ***:**:.* ** *:* *******:* **:*: 
 
FBXO9h          DG-FYRAWHQVEYYRYIRFFPDGHVMMLTTPEEPQSIVPRLRTRNTRTDAILLGHYRLSQ 333 
CG5961          QDQFYRPVQLVEYYRYIRFLPDGKVLMMTTADEPAQGVSKLKHVNNVRAEMLRGRYRLFG 343 
                :. ***. : *********:***:*:*:**.:** . *.:*:  *.    :* *:***   
 
FBXO9h          DTDNQTKVFAVITKKKEEKPLDYKYRYFRRVPVQEADQSFHVGLQLCSSGHQRFNKLIWI 393 
CG5961          -----STVTLVLQKSQQRGPANVRQRRGSIMPVDEDSSQFLIELRIAGTTKRRCAQLVWS 398 
                     :.*  *: *.::. * : : *    :**:* ...* : *::..: ::*  :*:*  
 
FBXO9h          HHSCHITYKSTGETAVSAFEIDKMYTPLFFARVRSYTAFSERPL- 437 
CG5961          HY-TLVQKRNKVDISSEFDLTEAKYPALRFSTVKSYHLDADAPLA 442 
                *:   :  :.. : : .    :  *..* *: *:**   :: **  
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S3.2. Statistical breakdown and comparison of ommatidia and bristle number counts between 
lacZ control and FBXO9 transgene constructs in the Drosophila melanogaster eye 
A. Ommatidia Number 25°C, control mean 752.4 ommatidia per eye 
Genotype Number of 
eyes (N) 
Mean difference in 
number vs control 
p-value 
compared to 
control 
Standard 
Deviation 
GMR-Gal4;UAS-lacZ 10 N/A N/A 25.012 
GMR-Gal4;UAS-
FBXO9RNAi 
10 39.40 <0.05 32.93765 
GMR-Gal4;UAS-FBXO9 10 43.60 <0.05 22.40932 
 
B. Ommatidia Number 29°C, control mean 714.40 ommatidia per eye 
Genotype Number of 
eyes (N) 
Mean difference in 
number vs control 
p-value 
compared to 
control 
Standard 
Deviation 
GMR-Gal4;UAS-lacZ 10 N/A N/A 25.85085 
GMR-Gal4;UAS-
FBXO9RNAi 
10 21.90 >0.05 23.77323 
GMR-Gal4;UAS-FBXO9 10 45.40 <0.05 42.54148 
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C. Bristle Number 25°C, control mean 596.90 bristles per eye 
Genotype Number of 
eyes (N) 
Mean difference in 
number vs control 
p-value 
compared to 
control 
Standard  
Deviation 
GMR-Gal4;UAS-lacZ 10 N/A N/A 15.97533 
GMR-Gal4;UAS-
FBXO9RNAi 
10 81.00 <0.0001 31.29945 
GMR-Gal4;UAS-FBXO9 10 54.10 <0.001 31.68526 
 
 
 
D. Bristle Number 29°C, control mean 498.20 bristles per eye 
Genotype Number of 
eyes (N) 
Mean difference in 
number vs control 
p-value 
compared to 
control 
Standard 
Deviation 
GMR-Gal4;UAS-lacZ 10 N/A N/A 22.77816 
GMR-Gal4;UAS-
FBXO9RNAi 
10 27.10 >0.05 26.91324 
GMR-Gal4;UAS-FBXO9 10 6.30 >0.05 71.58592 
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S3.3. Log-rank (mantel cox) survival analysis comparison of altered FBXO9 transgene constructs 
with lacZ control 
Genotype Number 
of Flies 
(N) 
Median 
Survival 
(Days) 
p-value 
compared to 
control 
Significant 
Ddc-Gal4;UAS-
lacZ 
292 54 N/A N/A 
Ddc-Gal4;UAS-
FBXO9RNAi 
286 45 <0.0001 Yes 
Ddc-Gal4;UAS-
FBXO9 
194 48 <0.0001 Yes 
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Appendix 4 – Supplemental Material for Chapter 5 
S4.1. Alignment and annotation of Homo sapiens ZNF746 protein (PARIS) with Drosophila 
melanogaster CG15436.  Alignment done with ClustalW, Yellow highlight = zinc finger 
domain, green highlight = KRAB / ZAD domain 
 
 
ZNF746          MAEA--VAAPISPWTMAATIQAMERKIESQAARLLSLEGRTGMAEKKLADCEKTAVEFGN 58 
CG15436         MAEICRVCMDIS-GKLVNIFDARRRTRVSIA-------------------------EMIA 34 
                ***   *.  **  .:.  ::* .*.  * *                         *:   
 
ZNF746          QLEGKWAVLGTLLQEYGLLQRRLENVENLLRNRNFWILRLPPGSKGESPKEWGKLEDWQK 118 
CG15436         QCTGFEVKRGDLFSEMICPQ---------------------------------------- 54 
                *  *  .  * *:.*    *                                         
 
ZNF746          ELYKHVMRGNYETLVSLDYAISKPEVLSQIEQGKEPCNWRRPGPKIPDVPVDPSPGSGPP 178 
CG15436         ---------CYEDVKSAYGIRQTCEESHQFY-----CRVR-------------------- 80 
                          ** : *     .. *   *:      *. *                     
 
ZNF746          VPAPDLLMQIKQEGELQLQEQQALGVEAWAAGQPDIGEEPWGLSQLDSGAGDISTDATSG 238 
CG15436         ----------------------------------DEGIEDALCALLEEEDWEISEDEDAR 106 
                                                  * * *    : *:.   :** *  :  
 
ZNF746          VHSNFSTTIPPTSWQTDLPPHHPSSACSDGTLKLNTAASTEADVKIVIKTEVQEEEVVAT 298 
CG15436         IDS-------------------ASAADDDG--KS--------DSKKVAFECR--ECHKKY 135 
                :.*                   .*:* .**  *         * * *       *      
 
ZNF746          PVHPTDLEAHGTLFGPGQATRFFPSPAQEGAWESQGSSFPSQDPVLGLREPARPERDMGE 358 
CG15436         QRKGTFLRHMRTHMD--------------------GQSFPCPYCKR-------------- 161 
                  : * *.   * :.                    *.***.                    
 
ZNF746          LSPAVAQEETPPGDWLFGGVRWGWNFRCKPPVGLNPRTGPEGLPYSSPDNGEAILDPSQA 418 
CG15436         ------------------------NFRLRVTLKAHMKTHNAAKPYECS------------ 185 
                                        *** : .:  : :*   . **...             
 
ZNF746          PRPFNEPCKYPGRTKGFGHKPGLKKHPAAPPGGRPFTCATCGKSFQLQVSLSAHQRSCGA 478 
CG15436         -----------HCAKTFAQQSTLQSHERTHTGERPFKCSQCSKTFIKSSDLRRHIR---- 230 
                             :* *.::. *:.*  : .* ***.*: *.*:*  . .*  * *     
 
ZNF746          PDGSGPGTGGGGSGSGGGGGGSGGGSARDGSALRCGECGRCFTRPAHLIRHRMLHTGERP 538 
CG15436         ----------------------THGSERP---FKCSKCTKTFTRKFHLDNHFRSHTGERP 265 
                                        ** *    ::*.:* : ***  ** .*   ****** 
 
ZNF746          FPCTECEKRFTERSKLIDHYRTHTGVRPFTCTVCGKSFIRKDHLRKHQRNHAAGAKTPAR 598 
CG15436         FKCSHCPKAFAMKQHLKQHSRLHLPDRPFRCSHCPKTFRLSSTLKEHKLVHNAER----- 320 
                * *:.* * *: :.:* :* * *   *** *: * *:*  .. *::*:  * *        
 
ZNF746          GQPLPTPPAPPDPFKSP--ASKGP----LASTDLVTDWTCGLSVLGPTDGGDM 645 
CG15436         ------------TFKCPHCASFYKQRKTLARHILEIHK--------------- 346 
                            .**.*  **       **   *  .                 
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S4.2. Statistical breakdown and comparison of ommatidia and bristle number between PARIS 
candidate RNAi transgene constructs and lacZ control.    
 
A. Ommatidia Number 25°C, control mean 758.6 ommatidia per eye 
Genotype Number of 
eyes (N) 
Mean difference in 
number vs control 
p-value 
compared to 
control 
Standard  
Deviation 
GMR-Gal4;UAS-lacZ 10 N/A N/A 3.130495 
GMR-Gal4;UAS-CROLRNAi 10 62.20 <0.0001 6.503845 
GMR-Gal4;UAS-CG15269RNAi 10 60.00 <0.001 35.57808 
GMR-Gal4;UAS-CG15436RNAi 10 2.800 >0.05 17.12308 
 
B. Ommatidia Number 29°C, control mean 726.2 ommatidia per eye 
Genotype Number of 
eyes (N) 
Mean difference in 
number vs control 
p-value 
compared to 
control 
Standard 
Deviation 
GMR-Gal4;UAS-lacZ 10 N/A N/A 14.77159 
GMR-Gal4;UAS-CROLRNAi 10 402.20 <0.0001 19.55761 
GMR-Gal4;UAS-CG15269RNAi 10 268.00 <0.0001 25.73325 
GMR-Gal4;UAS-CG15436RNAi 10 18.40 >0.05 18.33576 
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C. Bristle Number 25°C, control mean 599.6 bristles per eye 
Genotype Number of 
eyes (N) 
Mean difference in 
number vs control 
p-value 
compared to 
control 
Standard 
Deviation 
GMR-Gal4;UAS-lacZ 10 N/A N/A 13.2212 
GMR-Gal4;UAS-CROLRNAi 10 98.60 <0.0001 23.90607 
GMR-Gal4;UAS-CG15269RNAi 10 33.40 >0.05 44.7236 
GMR-Gal4;UAS-CG15436RNAi 10 -4.60 >0.05 23.12358 
 
D. Bristle Number 29°C, control mean 559.4 bristles per eye 
Genotype Number of 
eyes (N) 
Mean difference in 
number vs control 
p-value 
compared to 
control 
Standard 
Deviation 
GMR-Gal4;UAS-lacZ 10 N/A N/A 18.17416 
GMR-Gal4;UAS-CROLRNAi 10 251.20 <0.0001 35.20937 
GMR-Gal4;UAS-CG15269RNAi 10 98.20 <0.0001 19.07092 
GMR-Gal4;UAS-CG15436RNAi 10 25.80 >0.05 31.18974 
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S4.3. Statistical breakdown and comparison of ommatidia and bristle number between PARIS 
candidate RNAi transgene construct CG15436, srl constructs and lacZ control.    
 
A. Ommatidia Number 25°C, control mean 758.6 ommatidia per eye 
Genotype Number of 
eyes (N) 
Mean difference in 
number vs control 
p-value 
compared to 
control 
Standard 
Deviation 
GMR-Gal4;UAS-lacZ 10 N/A N/A 2.951459 
GMR-Gal4;UAS-srl 10 24.20 >0.05 16.34489 
GMR-Gal4;UAS-srlRNAi 10 32.40 >0.05 59.60015 
GMR-Gal4;UAS-CG15436RNAi 10 2.800 >0.05 17.28712 
 
 
B. Ommatidia Number 29°C, control mean 726.2 ommatidia per eye 
Genotype Number of 
eyes (N) 
Mean difference in 
number vs control 
p-value 
compared to 
control 
Standard 
Deviation 
GMR-Gal4;UAS-lacZ 10 N/A N/A 13.92679 
GMR-Gal4;UAS-srl 10 40.00 <0.05 28.81666 
GMR-Gal4;UAS-srlRNAi 10 176.00 <0.0001 52.82161 
GMR-Gal4;UAS-CG15436RNAi 10 18.40 >0.05 16.1438 
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C. Bristle Number 25°C, control mean 599.6 bristles per eye 
Genotype Number of 
eyes (N) 
Mean difference in 
number vs control 
p-value 
compared to 
control 
Standard 
Deviation 
GMR-Gal4;UAS-lacZ 10 N/A N/A 12.46506 
GMR-Gal4;UAS-srl 10 37.60 <0.05 9.614803 
GMR-Gal4;UAS-srlRNAi 10 46.00 <0.001 6.834553 
GMR-Gal4;UAS-CG15436RNAi 10 -4.600 >0.05 21.80112 
 
D. Bristle Number 29°C, control mean 559.4 bristles per eye 
 
Genotype Number of 
eyes (N) 
Mean difference in 
number vs control 
p-value 
compared to 
control 
Standard 
Deviation 
GMR-Gal4;UAS-lacZ 10 N/A N/A 17.13476 
GMR-Gal4;UAS-srl 10 36.70 <0.05 26.20454 
GMR-Gal4;UAS-srlRNAi 10 170.70 <0.0001 43.40264 
GMR-Gal4;UAS-CG15436RNAi 10 25.80 >0.05 29.40597 
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S4.4. Log-rank (mantel cox) survival analysis comparison of PARIS homologue candidate RNAi 
transgene constructs with lacZ control. 
Genotype Number of Flies 
(N) 
Median Survival 
(Days) 
p-value compared 
to control 
Significant 
Ddc-Gal4;UAS-lacZ 201 60 N/A N/A 
Ddc-Gal4;UAS-CROLRNAi 267 56 0.0192 Yes 
Ddc-Gal4;UAS-CG15269RNAi 179 62 0.9885 No 
Ddc-Gal4;UAS-CG15436RNAi 163 64 0.0005 Yes 
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